All conditions

Brain Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

3144
Trials on record
581
Recruiting now
13
Australian sites
28
Phase 3 trials
4
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Brain Cancer →

Get alerts when Brain Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Brain Cancer

Brain cancer occurs when abnormal cells grow and multiply in the brain, forming a mass called a tumour. These tumours can either start in the brain itself (called primary brain tumours) or spread to the brain from cancer elsewhere in the body (called secondary or metastatic brain tumours). Not all brain tumours are cancerous, but malignant ones can interfere with how the brain normally works by pressing on surrounding tissue or invading healthy brain cells. Brain cancers are graded according to how quickly they are likely to grow and spread, with higher grades generally being more aggressive.

In Australia, around 1,900 people are diagnosed with a primary brain tumour each year, and brain cancer can affect people of any age, including children. It is one of the more serious cancer diagnoses, and it is completely understandable to feel overwhelmed when first receiving this news. Support is available through your medical team, as well as organisations like the Brain Tumour Alliance Australia.

Treatment for brain cancer generally depends on the type, size, location, and grade of the tumour, as well as the age and overall health of the person diagnosed. Common approaches that doctors may use include surgery to remove as much of the tumour as safely possible, radiation therapy to target remaining cancer cells, and chemotherapy to slow or stop tumour growth. These treatments are sometimes used on their own and sometimes in combination. Your specialist team will explain what options are most relevant to your specific situation, and there may also be opportunities to take part in clinical trials that are testing newer approaches.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Brain Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Brain Cancer

4 medicines listed on the PBS for Brain Cancer. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 4 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Carmustine Gliadel Glioblastoma multiforme AU$10988.32 Restricted benefit
Temozolomide APO-Temozolomide, Temizole 5, Temizole 20 +1 more Glioblastoma multiforme AU$4.74 Restricted benefit
Dabrafenib Tafinlar Paediatric high grade glioma AU$3264.44 Authority required
Trametinib Mekinist Paediatric high grade glioma AU$576.8 Authority required
Dabrafenib Tafinlar Paediatric low grade glioma AU$3264.44 Authority required
Trametinib Mekinist Paediatric low grade glioma AU$576.8 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Brain Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Brain Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Brain Cancer by country. Australia is highlighted.

Showing the top 10 of 54 countries with trial sites.

Clinical trials for Brain Cancer

Showing 585 of 585 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT01189266 · National Cancer Institute (NCI) Phase 2 · 3 countries Completed
Completed Phase 2 Est. completion 30 June 2017
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been newly diagnosed with a type of brain tumor called a diffuse intrinsic pontine glioma (DIPG), meaning the tumor is centered in the brainstem and covers a large portion of it — no biopsy is needed to confirm this type; OR you have a brainstem tumor that has been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02617589 · Bristol-Myers Squibb Phase 3 · 19 countries Completed
Completed Phase 3 Est. completion 17 January 2019
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇱 IL +11 more

**Who might be able to join this trial:** - You are 18 years old or older (male or female) - You have been recently diagnosed with a type of brain cancer called glioblastoma (also known as GBM) - Your tumor test results show a specific characteristic called "MGMT unmethylated" (confirm with trial site if unsure of your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06728150 · Monash University Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 31 December 2029
🇦🇺 AU

**Who might be able to join this trial:** - You have breast cancer that has spread (metastasized) to organs, lymph nodes, or bones - Your breast cancer tests positive for a protein called HER2 (known as HER2-positive) - You have a type of breast cancer called triple negative breast cancer (TNBC) that has spread to othe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT00196742 · Genzyme, a Sanofi Company Not Applicable · 44 countries Recruiting
Recruiting Not Applicable Est. completion 31 January 2034
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL🇨🇳 CN +36 more

**Who might be able to join this trial:** **Fabry Registry:** - People who have a confirmed diagnosis of Fabry disease, meaning they have documented low levels of a specific enzyme (alpha-galactosidase) in their blood or white blood cells, and/or a known change (mutation) in the gene related to that enzyme. - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT04684368 · Children's Oncology Group Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 21 December 2029
🇦🇺 AU🇨🇦 CA🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - People who are aged 3 years or older and under 30 years old at the time of joining the study - People who have been newly diagnosed with a specific type of brain tumour (called a non-germinomatous germ cell tumour, or NGGCT) located in the suprasellar region (near the base o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05009992 · University of California, San Francisco Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇦🇺 AU🇮🇱 IL🇳🇱 NL🇳🇿 NZ🇨🇭 CH🇺🇸 US

Who might be able to join this trial: **General (most cohorts, ages 2–39):** - People aged 2 to 39 years with a diagnosis of a brain or spinal cord tumour called Diffuse Midline Glioma (DMG), confirmed by imaging and/or tissue testing - People whose body weight is at least 10 kilograms - People whose blood counts, kid...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05230758 · Donald Mabbott Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 30 November 2027
🇦🇺 AU🇨🇦 CA

Who might be able to join this trial: - People who finished primary treatment for medulloblastoma, ependymoma, craniopharyngioma, germ cell tumours, another brain tumour treated with radiation to the head, or radiation for relapsed ependymoma — and at least 3 weeks have passed since that treatment ended. - People aged...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05450744 · Telix Pharmaceuticals (Innovations) Pty Limited Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇦🇺 AU🇦🇹 AT🇳🇱 NL

**Who might be able to join this trial:** - People who are able to understand and sign a consent form before any study procedures begin - People who are 18 years of age or older, whether male or female - People who have been diagnosed with glioblastoma (a type of brain tumour) confirmed by laboratory testing of tissue...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05504772 · Australian & New Zealand Children's Haematology/Oncology Group Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇦🇺 AU🇳🇿 NZ

Who might be able to join this trial: - People who are under 18 years old (note: in some cases, people aged 19–25 with a childhood cancer such as neuroblastoma may also be considered, at the discretion of the Study Chair or their representative) - People who are expected to live for more than 6 weeks at the time of joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05839379 · Nationwide Children's Hospital Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 28 August 2029
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇳🇱 NL🇳🇿 NZ🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - People between 12 months and 39 years of age at the time of joining the screening process - People who have been newly diagnosed with a high-grade brain tumour (including a type called DIPG), where the diagnosis has been confirmed through a biopsy or surgical removal of tumour ti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05843253 · Nationwide Children's Hospital Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 31 August 2029
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇳🇿 NZ🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 12 months to 39 years old at the time of initial screening (for the early feasibility part of the trial, only people under 21 years old are eligible) - People who have been newly diagnosed with a high-grade brain tumour (HGG), including a type called DIPG, confir...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06838676 · Nationwide Children's Hospital Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - People who are at least 12 months old and no older than 39 years old at the time of joining the study. - People in Cohort A (newly diagnosed): Those diagnosed with a specific type of brain tumour called DIPG, based on MRI scans showing the tumour in the brainstem area, who h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06951659 · The University of Western Australia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 December 2025
🇦🇺 AU

Who might be able to join this trial: - Adults aged 18 to 80 who have been admitted to Sir Charles Gairdner Hospital (SCGH) under the neurosurgery team with a confirmed brain tumour diagnosis. - People who undergo a partial or full surgical removal of a brain tumour and are in a medically stable condition. - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT07100730 · Telix Pharmaceuticals (Innovations) Pty Limited Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 July 2027
🇦🇺 AU🇦🇹 AT🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of brain tumour called glioblastoma (IDH-wildtype), confirmed by a pathology test and classified according to 2021 WHO guidelines. - People whose glioblastoma has come back or grown for the first time after initial treatmen...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07363057 · GI Innovation, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇦🇺 AU

Who might be able to join this trial: - People aged 18 to 80 years old at the time of signing the consent form. - People whose general health is not severely compromised — meaning no life-threatening illness or disability, as assessed by the trial doctor. - People with a history of cancer may be considered if they have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07465796 · Coherence Neuro Australia Pty Limited Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇦🇺 AU

Who might be able to join this trial: - People who have been newly diagnosed with a type of brain tumour called a supratentorial glioma that needs to be surgically removed - People whose tumour reaches or is close to the surface of the brain - Adults between 18 and 75 years of age - People whose surgery is planned to b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT03419403 · AbbVie Phase 3 · 5 countries Terminated
Terminated Phase 3 Est. completion 5 September 2019
🇦🇺 AU🇩🇪 DE🇳🇱 NL🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been newly diagnosed with a specific type of brain tumor called glioblastoma (Grade IV GBM or Grade IV gliosarcoma), confirmed by a biopsy or tissue sample - Your tumor shows a specific genetic change called EGFR amplification (your doctor can check this from your tu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00083512 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

Who might be able to join this trial: - People aged 18 years or older. - People who have been diagnosed with a specific type of brain tumour called Glioblastoma multiforme, located in the upper part of the brain, confirmed through tissue testing. - People with a Karnofsky performance score above 60, which means a docto...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00461188 · Barts & The London NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2037
🇬🇧 GB

Who might be able to join this trial: - People who have acromegaly (a hormonal condition caused by excess growth hormone) that runs in their family, or another type of pituitary tumour that affects multiple family members - People who developed acromegaly at an unusually young age - People who have a pituitary tumour t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00599092 · Cedars-Sinai Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2050
🇺🇸 US

Who might be able to join this trial: - People with a confirmed diagnosis of a pituitary disease (a condition affecting the pituitary gland, a small gland at the base of the brain) Who may not be able to join: - People who do not have a confirmed diagnosis of a pituitary disease Important: Always verify eligibility w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00870129 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People who have a suspected or confirmed diagnosis of a high-grade or low-grade brain tumour (glioma), or whose tumour is suspected to have a specific genetic change called an IDH mutation - People who may be receiving radiation therapy as part of their treatment - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01535430 · University of Nebraska Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People aged 19 years or older - People who have a brain tumour located in or near areas of the brain that control important functions, where surgery to remove it may be considered - People whose body size and mental state allow them to safely take part in brain mapping procedures...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01668082 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People of any age, gender, race, or ethnic background - People who speak Spanish as their primary language - People who have had brain imaging (such as an MRI) that suggests a brain tumor, or who have had a biopsy of a tumor, before planned surgery to remove it - People who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01891318 · Case Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People who have previously been diagnosed with cancer (confirmed by tissue testing), except for small cell lung cancer, lymphoma, or germ cell cancers - People whose MRI scan shows between 1 and 4 tumours that have spread to the brain, with at least one tumour measuring more than...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01906385 · Plus Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 18 years old. - People who are able to understand the study's purpose and risks, and have signed a consent form approved by the relevant ethics committee. - People who have been diagnosed through a tissue biopsy with a Grade III or IV recurrent glioma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02290834 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇺🇸 US

Who might be able to join this trial: **Group 1 – Breast cancer patients receiving chemotherapy:** - You have been newly diagnosed with invasive breast cancer, confirmed by a tissue test (biopsy) - Your treatment plan includes chemotherapy - You are a woman aged 60 or older - Your doctors expect you to live at least 1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02394626 · Insel Gruppe AG, University Hospital Bern Phase 2 · 9 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇦🇹 AT🇫🇷 FR🇩🇪 DE🇬🇷 GR🇳🇱 NL🇵🇹 PT🇪🇸 ES🇸🇪 SE +1 more

"Who might be able to join this trial: - The person must be willing and able to provide written consent to participate. - The person must be 18 years of age or older. - The person must have previously had surgery to remove a glioblastoma (a type of brain tumour), confirmed by laboratory testing of the tissue. - The per...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02417324 · Universitätsklinikum Hamburg-Eppendorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with one of the specific brain or spinal cord tumour types this trial covers (please confirm the exact tumour types with the trial site) - Your tumour can be located anywhere in the body where these tumour types occur - You can be at any stage of your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02479698 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 2 years old or older (both English and non-English speakers are welcome). - You have a weakened immune system, and/or you have a brain infection caused by JC virus (called PML), and/or you have any type of cancer, and/or you have HIV/AIDS, and/or you have had a solid...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02504788 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇹🇼 TW

Who might be able to join this trial: - People who have been diagnosed with a solid (non-blood) cancer that has been confirmed by laboratory testing, and who have been referred for whole-brain radiation therapy for treatment or prevention purposes. - People who are in reasonably good general health, as measured by stan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02619890 · Asan Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2040
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with a brain glioma (a type of brain tumour), confirmed by both imaging scans and tissue testing - People with a life expectancy of more than 3 months - People who are receiving their first or second round of treatment for this condition - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02686229 · University of Ulm Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇪 DE

Who might be able to join this trial: - People who have brain imaging results that suggest they may have a low grade glioma (a type of slow-growing brain tumour) - People who are 18 years of age or older (there is no upper age limit) Who may not be able to join: - People who have a serious neurological or psychiatric...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02691923 · David W. Roberts Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed before surgery with a suspected first-time brain tumour known as a low or high grade glioma (including types such as astrocytoma, oligodendroglioma, mixed oligo-astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme) - People whose tumo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02747303 · University of Chicago Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 August 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who are reasonably active and able to care for themselves (as assessed by a standard medical scale called ECOG Performance Status 0–2), and who are expected to live for at least 3 months. - People who have a confirmed cancer that has spread to the bra...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02754544 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older who are having surgery to remove a brain tumor (either newly diagnosed or returning) at the University of Texas M. D. Anderson Cancer Center, where the tumor is in or near the parts of the brain that control movement or speech. - People who have given thei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02800486 · Northwell Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2035
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older. - People who have a confirmed diagnosis (from a tissue sample) of a brain tumour that has come back or stopped responding to treatment — specifically glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), or anaplastic oligoastrocytoma (AOA). - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02824731 · Technische Universität Dresden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇩🇪 DE

**Who might be able to join this trial:** - People who have a primary brain tumour, such as gliomas (slow- or fast-growing), meningiomas inside the brain, pituitary adenomas, craniopharyngiomas, or other rare brain tumours - People whose brain tumour has come back and who have not previously had radiation treatment -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02896335 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People whose cancer has been confirmed by laboratory testing of a tissue or cell sample — either any solid tumour (Group 1) or breast cancer specifically (Group 2). - People who have at least one measurable brain tumour or brain lesion that is 10mm or larger in size. - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02914067 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇺🇸 US

Who might be able to join this trial: **Cohort 1 – Newly diagnosed brain tumor (up to 30 participants)** - Children and young people aged 4 to 18 years old - Recently diagnosed with a primary brain tumor of any type or location - Expected to live for at least one year - Able to understand the study and willing to agre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02977780 · Patrick Wen, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma or gliosarcoma (specific types of brain tumour) confirmed by laboratory testing of tumour tissue, after having as much of the tumour removed by surgery as possible, where the tumour is located in the upper part of the brain. -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03005132 · Shanghai 10th People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are 75 years old or younger and have a confirmed diagnosis of glioblastoma (a type of brain tumour), proven through a tissue sample test - People whose heart, lungs, liver, kidneys, and other major organs are working well, without serious problems - People who have a W...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03014687 · St. Joseph's Hospital and Medical Center, Phoenix Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 January 2019
🇺🇸 US

Who might be able to join this trial: - People who are adults (aged 18 to 85) having endoscopic (keyhole, through the nose) surgery to remove a pituitary tumour, specifically a non-functioning adenoma, acromegaly-related tumour, or prolactinoma - People who speak English and are able to understand and complete two spec...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03067467 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a brain tumour (such as glioma, meningioma, or brain metastases) confirmed by imaging, before receiving any chemotherapy or radiation treatment - People between 18 and 70 years of age - People who are able to understand the study and are w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03122197 · University of Cincinnati Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - Your brain tumor (high-grade glioma) has come back, and this has been confirmed by a scan, tissue sample, or cell sample — and there is a plan for surgery or biopsy (or, for a sub-part of the trial, surgery or biopsy may not be required). - You are older than 18 years of age...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT03137095 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇺🇸 US

**Who might be able to join this trial:** *For breast cancer patient participants:* - Women who have been diagnosed with invasive breast cancer that has not spread to other parts of the body (stages I through IIIC) - People who are scheduled to start a chemotherapy treatment plan using the drugs Adriamycin and Cytoxan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03144167 · Centre Hospitalier Universitaire, Amiens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 January 2027
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged between 18 and 88 years who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by laboratory testing of tumour tissue, and whose cancer has come back for the first time after standard treatment involving surgery, chemotherapy with temozolom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03184038 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson Universi... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a solid tumour cancer that has been confirmed by a medical test (not small cell lung cancer or germ cell tumour) - You are reasonably active and able to carry out daily activities, as measured by a standard health scale (confirm with trial site)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03213002 · Northwell Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand and agree to participate by giving informed consent - People who have been confirmed by pathology testing to have a newly diagnosed Grade IV Glioblastoma Multiforme (a type of brain tumour) - People who have finished the first 6-week phase o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03270059 · OHSU Knight Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 December 2027
🇺🇸 US

Who might be able to join this trial: - People who have neurological symptoms such as headaches, seizures, loss of consciousness, weakness, or nerve-related problems. - People who have an abnormality found in the brain on a scan, whether or not it is related to cancer. - People who have a cancer elsewhere in their body...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03286335 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a brain tumor (either non-cancerous or cancerous) that has been confirmed by biopsy, or in some cases diagnosed through scans and clinical assessment without a biopsy, where radiation treatment is considered appropriate without one — common examples include l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03324360 · Sunnybrook Health Sciences Centre Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
🇨🇦 CA

Who might be able to join this trial: - Adults of any ethnic background aged 18 or older (specific age ranges and gender requirements apply depending on which group a person is enrolled in — confirm with trial site) - People aged 60 or older who have been diagnosed with mild cognitive impairment (for one specific grou...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03343873 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Men between 18 and 65 years old - Either healthy volunteers or people who have been diagnosed with a brain tumor - People who have completed senior high school or a higher level of education - People who are willing and able to sign a consent form agreeing to take part **Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03364803 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 14 or older - People who have been diagnosed with Cushing's syndrome that is currently active or has been treated, where the cause is a tumor on the pituitary gland, a tumor in another part of the body (ectopic), or a tumor on the adrenal gland - People diagnosed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03449238 · Weill Medical College of Cornell University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People whose general health and ability to carry out daily activities meets a specific fitness level used in cancer research (ECOG performance status 0–1; confirm with trial site) - Men and women (pre- or post-menopausal) who have been diagnos...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03510208 · Stanford University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have a suspected or confirmed diagnosis of glioblastoma (a type of brain tumor) — this applies to groups 1, 2, and 3 in the trial - People who have a suspected or confirmed diagnosis of vestibular schwannoma (a non-cancerous tumor near the ear and brain) — this ap...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03526822 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇫🇷 FR

Who might be able to join this trial: - You are 18 years of age or older, either male or female - Your brain scans suggest you may have glioblastoma (a type of brain tumor) - Your doctors have determined you are suitable for surgery to remove the tumor (fully or partially) - You are planned to receive the standard comb...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03534050 · Chang Gung Memorial Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 July 2026
🇹🇼 TW

Who might be able to join this trial: - People who have been diagnosed with a slow-growing, spread-out type of brain tumour (low-grade glioma) and have had surgery to remove all or part of the tumour, or at least a biopsy to confirm the diagnosis. - People whose doctors recommend brain radiation therapy because of high...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03550391 · Canadian Cancer Trials Group Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2027
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have between 5 and 15 spots of cancer that have spread to the brain, as seen on a specific type of brain scan (MRI with contrast dye) taken within the last 30 days. - People who have a confirmed diagnosis of a solid tumour cancer (not a blood cancer), confirmed by...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03596086 · David Baskin MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis (proven by biopsy) of recurring anaplastic astrocytoma or glioblastoma multiforme, without the tumour appearing in multiple separate areas of the brain or in the brainstem. - People whose brain scans show signs that the tumour has come b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03603405 · The Methodist Hospital Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of brain tumor (anaplastic astrocytoma or glioblastoma multiforme), confirmed by a biopsy taken during surgery, that has not spread to multiple separate areas of the brain or into the brainstem. - Your doctor expects you to live f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03649880 · OHSU Knight Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults over 18 years old who have a known or suspected brain tumour. - People who are able to give written consent themselves, or who have a trusted representative able to give consent on their behalf. - People whose brain tumour lesion is larger than 10 mL in size, as measu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03684109 · University of Miami Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

Who might be able to join this trial: - You must be an adult aged 18 or older - You have a suspected or confirmed brain tumour (glioma) and your doctor has already recommended a biopsy or surgery to remove or sample the brain lesion Who may not be able to join: - Adults who are not able to give their own consent to pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03696680 · Centre Francois Baclesse Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are older than 18 years of age - You are generally well enough to carry out normal daily activities with little or no limitation (confirm with trial site) - You have fewer than 4 brain metastases (cancer that has spread to the brain from another part of the body, such as...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03728673 · University of Nebraska Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by laboratory testing to have a Grade IV glioma (a type of brain tumour) - People who have been recently diagnosed and are due to receive chemotherapy and/or radiation treatment - People whose general physical functioning falls within a certain...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03741673 · M.D. Anderson Cancer Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - The main brain tumour being treated must be no larger than 4 cm (for single-session treatment) or 7 cm (for multi-session treatment) before surgery - A person must be considered a suitable candidate for a type of targeted brain radiation (called SRS) within 30 days before or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03750227 · Mayo Clinic Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 8 November 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have a confirmed solid tumour (confirmed by tissue or cell testing), or who have a known or suspected cancer that has spread, with a brain tumour that doctors believe is a brain metastasis (cancer that has spread to the brain) based on cl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03830151 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - People who are willing to provide written agreement to take part in the study, including healthy volunteers. - Healthy volunteers who do not have any reason they cannot safely have an MRI scan. - People who are already enrolled in a related study called the Stereotactic RadPath t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03849430 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇧🇪 BE

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with and are receiving treatment for a type of brain tumour called a glioma (either a fast-growing or slow-growing type) - People whose treatment is taking place at UZ Leuven hospital Who may not be able to join: - No spec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03861299 · Jasper Gerritsen Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇧🇪 BE🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 to 90 years old - People whose brain scan (MRI) shows a specific type of brain tumour called Glioblastoma Multiforme, with a particular ring-shaped appearance and signs of dead tissue at the centre, as assessed by the surgeon - People whose tumour is located in or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03896568 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to give their consent, attend all study visits, and follow the study schedule - People who have been diagnosed with a returning (recurrent) brain tumour — specifically glioblastoma (GBM), gliosarcoma, a certain type of anaplastic astrocytoma w...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03911388 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You are at least 3 years old and younger than 22 years old - You have a cancerous brain tumor in the cerebellum (the lower back part of the brain) that has been confirmed by a tissue sample, and the tumor has come back or kept growing despite standard treatments like surgery...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04030507 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with breast cancer that has been confirmed through tissue or cell testing, with the cancer's hormone receptor and HER2 status identified. - People whose breast cancer has spread to distant parts of the body (outside the brain) or has come back in a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04033497 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a solid cancer that started outside the brain (confirmed by lab testing of tissue or cell samples) and who have at least one brain metastasis (cancer that has spread to the brain) that was previously treated with a focused form of radiatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04066465 · Technische Universität Dresden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇩🇪 DE

**Who might be able to join this trial:** - Children and teenagers between 8 and 18 years of age - People who have not previously had radiation treatment to the brain - People who are able to complete repeated thinking and memory tests, each lasting around one hour - People whose corrected vision (with glasses or cont...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04099797 · Baylor College of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People with a confirmed brain or central nervous system (CNS) tumour that tests positive for a protein called GD2, or has a specific genetic change called H3K27 alteration — this includes newly diagnosed tumours, as well as tumours that have come back, stopped responding to...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04109131 · Jules Bordet Institute Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇧🇪 BE🇫🇷 FR🇱🇺 LU

**Who might be able to join this trial:** - People aged 18 or older - People with a general health and activity level rated as reasonably functional (a standard cancer performance scale score of 2 or below) - People of any gender - **For Part A of the trial:** People with one of the listed cancer types that was either...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04111588 · Norwegian University of Science and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇳🇴 NO

**Who might be able to join this trial:** *For people with glioma (a type of brain tumour):* - People who have been diagnosed with or are planned to be treated for a WHO grade II, III, or IV diffuse glioma (a range of brain tumour types, from lower to higher severity) - Adults aged 18 years or older - People who are p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04115761 · Ever Supreme Bio Technology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇹🇼 TW

**Who might be able to join this trial:** - People who were between 20 and 75 years old at the time of their brain tumor surgery. - People who have been newly diagnosed with a single, primary Grade IV glioblastoma (a specific type of aggressive brain tumor) that is not located in the brainstem or cerebellum, and who a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04135807 · Oliver Jonas Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 21 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have a brain tumor located in the upper part of the brain (not the brainstem or deep structures) that imaging suggests is a type of glioma (grade II to IV), and where surgeons plan to remove all or part of the tumor. - People whose tumor has been confirmed as a gr...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04181684 · University of Maryland, Baltimore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a WHO Grade II, III, or IV brain tumour (glioma) that has come back or continued to grow, as shown on a brain scan - People who received radiation therapy as part of their original glioma treatment - People who have not previously had a se...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04185038 · Seattle Children's Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 1 and 26 years old - You have a brain or spinal cord tumor that has come back or stopped responding to treatment and there are no standard treatment options left, OR you have a specific type of brainstem tumor (DIPG or DMG) and have already finished standard t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04197297 · University Health Network, Toronto Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with a primary cancer (confirmed by a biopsy), and brain scans show that the cancer has spread to the brain - At least one of the tumors in the brain is larger than 1 cm across and shows no signs of bleeding on scans - You are 18 years of age or older...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04222062 · University of Nebraska Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

"Who might be able to join this trial: - People who are 18 years of age or older (or 19 and older if living in Nebraska). - People whose overall health and cancer situation falls within a certain range, as measured by standard medical scoring tools used for brain cancer patients, and who have a functional ability score...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04233788 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇭 CH

**Who might be able to join this trial:** - Healthy people who are able to lie still inside an MRI scanner for up to one hour - People who have been told they may have a growth or mass in their brain that needs further investigation - People who are willing and able to give written consent to take part **Who may not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04254419 · Nationwide Children's Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a brain or central nervous system (CNS) tumour that has come back, is getting worse, or has not responded to treatment (except for certain types called diffuse midline gliomas or DIPG). - The tumour diagnosis must have been confirmed by ex...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04267978 · Beijing Sanbo Brain Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 to 70 years old - People who have been diagnosed with a brain tumour called GBM (glioblastoma) or a lower-grade brain tumour (such as oligodendroglioma, astrocytoma, or related types), confirmed by tissue testing - People whose tumour has come back, either confirme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04274283 · University of Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇬🇧 GB

Who might be able to join this trial: - People who have been newly diagnosed with a suspected brain tumour (WHO Grade 2–4 glioma, based on scans) and are suitable for a surgical procedure that would provide a tumour sample alongside a blood sample. - People who have a previously diagnosed brain tumour (WHO Grade 2–4 gl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04297020 · Jonsson Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People between 35 and 65 years of age - People who are fluent in English - People with sufficient vision and hearing to complete the tests involved in the trial **Who may not be able to join:** - People who have been diagnosed with any form of dementia or memory/thinking dis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04343157 · Jona Hattangadi-Gluth Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People with one to three brain metastases (tumours that have spread to the brain), each smaller than 3 cm across, whether the tumour is still present or the area has been surgically removed - People who are reasonably well and able to carry ou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04348747 · Roswell Park Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 June 2027
🇺🇸 US

**Who might be able to join this trial:** - Women who are not pregnant, not breastfeeding, and either cannot become pregnant or agree to use acceptable birth control for the full duration of the study and until the study drug is no longer detectable in the blood (which may be several years); a combination of two birth...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04427384 · GT Medical Technologies, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have had surgery to remove as much of a brain tumour as safely possible, with a radiation device called GammaTiles placed in the brain during that same surgery. - People who are willing and able to agree to take part and to attend all required assessments and check...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04443010 · Philogen S.p.A. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇭 CH

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed with glioblastoma (a type of brain tumour) for the first time, confirmed by laboratory testing of tissue - People whose general health and ability to carry out daily activities meets a minimum functional score (called...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04479696 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 February 2027
🇺🇸 US

**Who might be able to join this trial:** **For patients:** - Adults who have recently been diagnosed with a brain tumour called glioma (graded 2 to 4 on the WHO scale) and are planned to have a 6-week course of radiation treatment after surgery - People who are able to complete questionnaires written in English - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04523688 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. I... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma (a type of brain tumour) that is confirmed by tissue testing and is located in a single area of the brain. - People who have had surgery that removed nearly all of the tumour, leaving no more than 5 ml of tumour remaining, as...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04547777 · Darell Bigner Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed (confirmed by tissue analysis) with a returning (recurrent) high-grade brain tumour (WHO grade 3 or 4 malignant glioma) located in the upper part of the brain (supratentorial region), including tumours with molecular features of glioblastoma. - For...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04559230 · The University of Texas Health Science Center at San Antonio Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who are able to understand what the study involves and have signed an approved consent form. - People who have been diagnosed with a specific type of brain tumour called IDH wild-type glioblastoma (GBM), gliosarcoma, or epith...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04569591 · National Institute of Neurological Disorders and Stroke (NINDS) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 8 or older who have been diagnosed with Cushing's disease based on medical records, with lab results confirming the condition - People whose MRI of the pituitary gland either showed no tumor or only a possible tumor (not a confirmed tumor) - People who had an MRI...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04573140 · University of Florida Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** **For adults with GBM (Group 1):** - People aged 21 years or older - People with a newly diagnosed brain tumour called glioblastoma (GBM, Grade IV), confirmed by laboratory testing, that has a specific molecular feature called MGMT low or unmethylated — this is not a tumour th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04623931 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with certain types of brain tumours called IDH wildtype gliomas, including diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytoma, or molecularly defined high-grade glioma o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04689048 · Baptist Health South Florida Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who are reasonably well and able to carry out daily activities (as assessed by their doctor using a standard scale called the ECOG scale, with a score of 0, 1, or 2) - People who have been diagnosed with cancer that has spread t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04692324 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have any sign of a tumour or growth affecting the brain, spine, nerves, blood vessels, or the membranes surrounding the brain and spinal cord — whether confirmed as cancer, non-cancerous, or not yet classified - People who are 18 years of age or older **Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04692337 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have clinical and imaging evidence suggesting a brain tumor - People who are already planned to have surgery to remove a suspected or confirmed brain tumor as part of their normal medical care - People who are willing to have their brain...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04699773 · University of Maryland, Baltimore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - You have brain scan (imaging) results that suggest you may have a fast-growing brain tumor called a high-grade glioma - A recent MRI scan with contrast dye (taken within the last 60 days) shows a tumor mass, and a neurosurgeon has confirmed you are a suitable candidate for a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04708171 · Erasmus Medical Center Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇧🇪 BE🇩🇪 DE🇳🇱 NL🇨🇭 CH🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 to 90 years old - People whose MRI scan shows a brain tumour diagnosed as glioblastoma (GBM) by a neurosurgeon - People whose tumour is located in or near important brain areas that control movement, sensation, speech, or vision, as shown on MRI - People whose...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04732065 · Sabine Mueller, MD, PhD Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 31 May 2027
🇳🇱 NL🇨🇭 CH🇺🇸 US

**Who might be able to join this trial:** *General requirements for all arms:* - Children and young adults aged 2 and above (some arms require age 2–21 for the dose escalation phase, with 2 and above for the dose expansion phase) with a confirmed brain or spinal cord tumour diagnosis, depending on which arm of the tri...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04765098 · AHS Cancer Control Alberta Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by laboratory testing of tumour tissue, whose cancer has come back or grown after completing standard first-line treatment (chemotherapy with temozolomide combined with radiotherapy). - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04765514 · AHS Cancer Control Alberta Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2032
🇨🇦 CA

**Who might be able to join this trial:** - People who have been newly diagnosed with glioblastoma (a type of brain tumour) that has been confirmed by tissue testing, and who have had as much of the tumour safely removed as possible (or a biopsy if removal was not possible). - People whose tumour has tested positive f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04790253 · European Organisation for Research and Treatment of Cancer - EORTC Not Applicable · 9 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇦🇹 AT🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL🇪🇸 ES🇨🇭 CH +1 more

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with small cell lung cancer (SCLC), confirmed by a tissue or cell sample - People with either limited-stage SCLC (cancer that has not spread widely, classified as Stage I–III, where the tumour and affected lymph...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04816006 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 50 or older at the time of joining the trial - People whose first and only primary breast cancer diagnosis was stage I to IIIa (not stage 0 and not spread to other parts of the body) - People who finished their main cancer treatments (such as surgery, chemotherap...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04817566 · University Medicine Greifswald Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇩🇪 DE

**Who might be able to join this trial:** - People who have received chemotherapy to treat breast cancer and finished treatment at least 6 months ago - People who have noticed concerns about their own memory or thinking since treatment - People aged between 18 and 65 years - People who are right-handed **Who may not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04833335 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 September 2028
🇫🇷 FR

Who might be able to join this trial: - People who have cancer that has spread to the brain (brain metastases), where the original cancer has been confirmed by laboratory testing of tumour tissue - People who have received Gamma Knife (a type of targeted radiation treatment) within the last 4 months before joining the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04847284 · Parc de Salut Mar Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇪🇸 ES

**Who might be able to join this trial:** - You are 18 years of age or older - You are generally able to carry out normal daily activities (your doctor has assessed your overall health and function as being at a reasonable level) - You have been newly diagnosed with a single tumor lesion in the brain (either in the mai...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04863950 · The University of Texas Health Science Center at San Antonio Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 18 years old - People who are able to understand the study's purpose and risks, and who have signed a written consent form approved by the ethics committee - People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed through...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04908709 · Emory University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 October 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a high-grade brain tumour (classified as grade 3 or 4 by the World Health Organization), either confirmed by tissue testing or strongly suspected based on brain scans (though tissue confirmation will be required to remain in the trial) - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04923126 · St. Jude Children's Research Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2031
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with, or are suspected to have, a low-grade brain tumour (a slow-growing type of brain tumour), including certain types of neuronal or mixed brain tumours, confirmed by a specialist review of tumour tissue - People whose tumour tissue is availa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04923542 · H. Lee Moffitt Cancer Center and Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 5 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with breast cancer that tests positive for hormone receptors (estrogen or progesterone), meaning at least 1% of cancer cells show hormone receptor activity on a lab test. - People whose breast cancer tests negative for a protein called HER2, meaning the canc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04943848 · Ann & Robert H Lurie Children's Hospital of Chicago Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with a specific type of brain tumor called DIPG or DMG, confirmed either by biopsy or by brain imaging that meets specific criteria (confirm with trial site for details on imaging requirements) - The tumor must have a confirmed histone mu...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04943913 · Shanghai Juncell Therapeutics Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been confirmed by tissue testing to have a primary, returned, or spread brain glioma (a type of brain tumour) - People whose life expectancy is estimated to be more than 3 months - People who have a reasonable level o...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04945148 · Hopital Foch Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 May 2028
🇫🇷 FR🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older - People who have been newly diagnosed with a specific type of brain tumour called IDH wild-type glioblastoma (Grade 4), located in the upper part of the brain, confirmed by tissue testing — including a type called gliosarcoma - People whose tumour te...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04962672 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇨🇦 CA

**Who might be able to join this trial:** - People who had an elective (planned, non-emergency) procedure scheduled between July 1, 2022 and December 28, 2023 - Adults aged 18 or older, of any gender - People who are having their first brain surgery (craniotomy, performed under general anaesthetic) for a suspected high...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04965064 · University of Rochester Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older, of any gender - People who have been diagnosed with breast cancer that has tested negative for the HER2 protein, based on the most recent tumour sample - People with hormone receptor-positive (ER positive) breast cancer who have already re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04977375 · Chirag G. Patil Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with a specific type of aggressive brain tumour called Glioblastoma Multiforme (Grade IV), confirmed by a tissue test - People whose brain tumour has come back or is growing again, and who are already planned to have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04991870 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have signed and dated a consent form agreeing to take part - People aged 12 years or older at the time of signing the consent form - People who have been diagnosed with a specific type of recurring brain tumour (a high-grade astrocytoma confirmed by tissue testing...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05013892 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a solid tumour (a non-blood cancer) that has spread to the brain, and whose doctor has recommended whole-brain radiation treatment - People aged 18 or older - People with a reasonably good level of physical functioning, as rated by their d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05014399 · Joseph McCollom Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a consent form agreeing to take part in the study before any study-related procedures begin - People who have been diagnosed with colorectal cancer confirmed through a tissue sample (biopsy) - People whose treatment plan includes one or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05023434 · Medical College of Wisconsin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old - You are able to read and understand a consent form, and are willing to sign it - An MRI scan has shown a tumor (one that does not light up with contrast dye) that is affecting the movement control area on the non-dominant side of your bra...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05033691 · Hadassah Medical Organization Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇮🇱 IL

**Who might be able to join this trial:** - People who have been newly diagnosed with metastatic non-small cell lung cancer (a type of lung cancer that has spread) that cannot be treated with surgery or radiotherapy aimed at a cure. - People whose lung cancer has a specific gene change (EGFR mutation) known to respond...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05045950 · Medical College of Wisconsin Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who were 18 years of age or older when their brain metastases were diagnosed - People whose general physical functioning is relatively good, meaning they are able to carry out most daily activities (confirmed using a standard medical scale called the ECOG score, which...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05049148 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇫🇷 FR

Who might be able to join this trial: - People who are scheduled to have a brain or spinal cord tumor removed or biopsied - People who are over 18 years old - People who have given their consent to take part in the study - People who are members of the French Social Security system Who may not be able to join: - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05050929 · British Columbia Cancer Agency Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a solid (non-blood) cancer - People who have cancer that has spread to the brain (brain metastases), regardless of size - People with any number of brain metastases — whether previously untreated or still growing...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05052957 · Leland Metheny Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma or gliosarcoma (a type of brain tumour) located in the upper part of the brain, confirmed by laboratory analysis of tumour tissue, and who have had surgery to remove most or all of the tumour (at least 85%) within the past 35...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05057702 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who have been previously diagnosed (confirmed by tissue testing) with medulloblastoma or ependymoma that has come back, and are experiencing their first or second relapse. - People whose tumour can be reached and removed or sampled through surgery, with enough tissue expec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05083754 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have been newly diagnosed with a specific type of aggressive brain tumour (Grade IV Glioblastoma or gliosarcoma), confirmed by laboratory testing, who had carmustine wafers placed in the brain during surgery - People who have had no prior treatmen...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05086497 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 22 years or older - People who have been diagnosed with glioblastoma (GBM), confirmed through laboratory testing of tumour tissue - People who have already had surgery to remove as much of the tumour as safely possible, followed by a full course of radiation ther...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05096481 · Nationwide Children's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 June 2028
🇺🇸 US

**Who might be able to join this trial:** **For people with returning or worsening medulloblastoma (a type of brain tumour) — Stratum I:** - People who are between 3 and 39 years old at the time of joining the trial. - People who have been diagnosed with medulloblastoma that has come back, is getting worse, or is not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05102747 · Centre Francois Baclesse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older. - People with a general health status rated as fully active or able to carry out light work (WHO performance status 0 or 1). - People who have been recommended for a type of targeted brain radiation treatment called stereotactic radiotherapy (SRT), f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05106296 · Theodore S. Johnson Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with ependymoma, medulloblastoma, glioblastoma, or another type of primary brain or spinal cord cancer that has come back or stopped responding to treatment, and for which no standard curative treatment options remain. - People whose cancer has...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05106725 · CureScience Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇺🇸 US

Who might be able to join this trial: - The person joining (or their legal representative) is able to understand and willing to sign and date a consent form agreeing to take part. - The person is 18 years of age or older. - The person has had or has a scheduled appointment with cancer or brain/nerve specialist services...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05124236 · Susanne Rogers Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇦🇹 AT🇩🇪 DE🇨🇭 CH

**Who might be able to join this trial:** - People aged 18 or older - People who have signed and dated a consent form and are willing to follow all study procedures for the full duration of the trial - People whose general health and ability to carry out daily activities meets a minimum level, as measured by a standar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05124912 · Monteris Medical Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have brain metastases (cancer that has spread to the brain from another part of the body) confirmed by a special type of MRI scan using a contrast dye - People who have at least one brain lesion that has grown back or worsened after previously being treated with f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05139277 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: - People who are over 18 years of age - People who have a suspected brain tumour (such as glioma, glioblastoma, brain metastasis, meningioma, acoustic neuroma, or pituitary adenoma) and who doctors have determined may be suitable for surgery - People who are able to understand and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05151718 · Institut Claudius Regaud Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - Children who have been diagnosed with a type of brain tumour called an ependymoma (a tumour that grows inside the skull) - Children who have already received treatment for this condition - Children who are already enrolled in one of three specific study programs: the PEPPI st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05215106 · Gustave Roussy, Cancer Campus, Grand Paris Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - Women aged 18 or older who have been diagnosed with a specific type of breast cancer confirmed by tissue testing (triple-negative breast cancer: ER less than 10%, PR less than 10%, HER2 negative), and who have not yet received any treatment for it - People whose breast cance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05222620 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People who have brain metastases (cancer that has spread to the brain) that are believed to have come from a cancer in another part of the body, such as the lung, breast, or prostate - People whose brain metastases include at least one untreat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05226494 · NanoPharmaceuticals LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma (a type of brain tumour) that has been confirmed by laboratory testing of tissue, and the tumour has come back for the first or second time. - People who are taking steroid medication at a stable or reducing dose at the time o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05254197 · Seoul National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2035
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with a low-grade brain tumour (graded 2 or lower by WHO standards) through medical imaging, either since 1998 (for the past-records group) or recently (for the ongoing group) - People who had no symptoms when they first visited the hospital for this...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05271240 · Northwell Health Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who have a confirmed diagnosis of a specific type of brain tumour called glioblastoma (GBM), classified according to 2021 world health standards, including certain tumour features seen under a microscope or specific genetic m...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05274919 · Leiden University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇳🇱 NL

**Who might be able to join this trial:** - People aged 18 years or older (required for all groups in the trial) - People who are scheduled to have a brain MRI scan with a contrast dye injection as part of their regular medical care (Group 1) - People who have been diagnosed with a suspected brain tumour called a glio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05278208 · Nationwide Children's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a high-grade brain or central nervous system (CNS) tumour (classified as WHO grade III or IV) or a meningioma (any grade) that has come back, is getting worse, or has not responded to treatment. - People with a type of childhood brainstem...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05278715 · Beijing Sanbo Brain Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People between 3 months and 21 years of age - People diagnosed with a type of brain tumour called an optic pathway glioma, confirmed either by a tissue biopsy or by a brain MRI scan combined with typical clinical signs - People whose tumour can be measured on scans, where less th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05281731 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have recently been diagnosed with a brain lesion that imaging suggests is glioblastoma multiforme (a type of brain tumour), where the scan was taken no more than 28 days before enrolling. - People whose brain lesion is larger than 3 cm at its widest point, as seen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05284643 · University of Miami Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with recurrent glioblastoma (or a related brain tumour type called gliosarcoma), confirmed by MRI scan, biopsy, or advanced imaging such as PET or special MRI techniques. - People whose diagnosis of glioblastoma or gliosarcoma meets the 2021 World H...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05287750 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 80 years old (inclusive) - You have been diagnosed with a brain condition, such as a brain tumor or a disease affecting the blood vessels in the brain - You are able to safely have an MRI scan and receive a contrast dye injected through a vein (no known rea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05293197 · Assistance Publique - Hôpitaux de Paris Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - Children and young people aged 5 years old up to (but not including) 18 years old - People who are able to undergo the trial's sound wave treatment and MRI scans without needing sedation - People who have been diagnosed with a certain type of cancerous brain tumour located i...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05298995 · Bambino Gesù Hospital and Research Institute Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇮🇹 IT

**Who might be able to join this trial:** - People between 6 months and 30 years of age - People whose brain tumour can be measured or assessed on at least two dimensions using MRI scans taken at the time of joining the trial - People who have had imaging scans done within 14 days before starting treatment - People wi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05303467 · Boston Scientific Corporation Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are willing and able to sign a consent form - People with a life expectancy of at least 12 weeks - People who are willing and able to follow the trial schedule, including tests, procedures, and follow-up visits - People who have a confirmed diagno...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05315895 · Guangzhou University of Traditional Chinese Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

Who might be able to join this trial: - You are between 30 and 79 years old, and you currently live at the same address listed on your official ID or registration documents - You are willing to take part in the study, agree to have your biological information (such as samples or health data) collected, and are happy to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05317858 · InSightec Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇨🇦 CA🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People who are willing to give written consent and follow all study procedures for the full duration of the trial. - People who have a reasonably good level of physical functioning, as measured by standard medical scoring tools (confirm with trial...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05326334 · Ottawa Hospital Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇨🇦 CA

**Who might be able to join this trial:** - People who have been newly diagnosed with a specific type of aggressive brain tumour called glioblastoma (WHO grade 4, IDH-1 R132H wild type) - People who have had surgery that removed at least 70% of the tumour - People aged 18 or older - People who are generally able to ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05331521 · University Hospital Heidelberg Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2033
🇩🇪 DE

**Who might be able to join this trial:** - People who have been newly diagnosed with a brain tumour (called a CNS glioma, grade 2 or 3), confirmed by laboratory testing of tumour tissue. - People whose tumour has a specific genetic change called an IDH mutation, identified through laboratory testing. - People whose t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05342454 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇺🇸 US

**Who might be able to join this trial:** *Prospective (forward-looking) part of the study:* - People aged 18 or older - People who are scheduled to have surgery to remove a brain tumor - People for whom a pre-surgery brain scan using fMRI (a type of imaging that shows brain activity) is already planned as part of the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05353530 · University of Florida Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been newly diagnosed with a specific type of brain tumour called GBM (Grade IV glioma) for the first time, confirmed by laboratory testing of tumour tissue — people with a secondary form of GBM are not eligible - People whose tumour...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05366179 · UNC Lineberger Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 May 2030
🇺🇸 US

Who might be able to join this trial: - People with a relatively good level of physical functioning, as measured by a standard medical scoring tool called the Karnofsky scale (confirm with trial site) - People who have been diagnosed with, or have a recurrence of, a type of brain tumour called glioblastoma multiforme (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05375617 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - Children and young people between 3 and 21 years old at the time of consent who have been newly diagnosed with a type of blood cancer called ALL (either B-cell, T-cell, or mixed type), confirmed by laboratory testing - Children and young people between 3 and 21 years old at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05378633 · University Hospital Heidelberg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 February 2027
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with a cancerous condition, confirmed through laboratory testing of tissue samples - People who have between 4 and 15 suspected brain lesions (abnormal areas) visible on MRI scans - People who are 18 years of age or older - Women who could become pr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05380349 · Swedish Medical Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of brain tumor called Glioblastoma (GBM, WHO grade 4), confirmed by a tissue sample (biopsy or surgery) - You are 18 years of age or older - Your doctors expect you to live for more than 6 months - Your tumor can be reached by surgery, and...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05386043 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 July 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 89 years old - People who have been diagnosed with, or are suspected to have, a brain tumour called a glioma (Grade II through IV, based on World Health Organization classification), as confirmed by a doctor - People who have not yet received any tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05386108 · Stemline Therapeutics, Inc. Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇧🇪 BE🇫🇷 FR🇩🇪 DE🇬🇷 GR🇮🇹 IT🇰🇷 KR🇪🇸 ES Turkey (Türkiye) +2 more

**Who might be able to join this trial:** - People who have signed a consent form before any study-related activities begin, in line with local guidelines. - Adults aged 18 or older at the time of signing the consent form. - Women who are post-menopausal (defined as being aged 60 or over; or under 60 with no menstrual...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05397873 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 April 2026
🇨🇦 CA

Who might be able to join this trial: - People who have previously been diagnosed with hemianopia (a condition where vision is lost in half of the visual field) confirmed through a type of vision test called microperimetry, along with any other tests needed - People aged between 18 and 90 years old - People who are abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05416567 · St. Olavs Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇳🇴 NO

Who might be able to join this trial: - People who have been diagnosed with a typical brain meningioma (a type of brain tumour) confirmed by imaging scan, showing specific characteristics such as uniform contrast uptake or attachment to the brain's protective lining - People whose tumour requires treatment because it h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05423210 · Stony Brook University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma multiforme, a type of brain tumour classified as WHO Grade IV (the most serious grade) - People whose doctors have determined they are suitable for surgery, with the goal of removing more than 80% of the tumour - People who ha...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05432518 · AHS Cancer Control Alberta Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 July 2027
🇨🇦 CA

**Who might be able to join this trial:** - You must be willing and able to give your agreement to participate before any study activities begin. - You must be an adult (18 or older) who has been diagnosed with a specific type of brain tumour called IDH-wild type glioblastoma, and your tumour has come back for the fir...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05432804 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of brain tumor called glioblastoma (with particular molecular features: IDH wild-type and MGMT promoter methylated), confirmed by a tissue sample, and the tumor has come back for the first time and been surgically removed or biops...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05439278 · Severance Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇰🇷 KR

**Who might be able to join this trial:** - People who have been newly diagnosed with glioblastoma (a type of brain tumour) based on the 2021 World Health Organization classification - People whose diagnosis was confirmed no more than 4 weeks before being enrolled in the trial - People aged 70 years or older - People...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05460507 · Plus Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 18 years old at the time of screening. - People who are able to understand the purpose and risks of the study and have signed a written consent form approved by the relevant review board. - People who have a brain tumour called glioma (confirmed by bi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05463848 · L. Nicolas Gonzalez Castro, MD, PhD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form. - People who are able to follow the visit and dosing schedule, and are willing to keep an accurate daily diary of when they take their medication. - People who are at least 18 years o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05464992 · Centre Paul Strauss Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 December 2036
🇫🇷 FR

Who might be able to join this trial: - People who have been admitted to the Nuclear Medicine and Molecular Imaging department at ICANS (Institut de Cancérologie Strasbourg Europe) for a combined PET/MRI scan - People having this scan to assess a brain lesion before surgery - People having this scan to check whether a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05465954 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older. - People who have been diagnosed (confirmed by tissue testing) with a specific type of aggressive brain tumour called Grade IV IDH wildtype glioblastoma (including types called molecular glioblastoma and gliosarcoma) that has come back or kept growin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05474378 · Stanford University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a high-grade brain tumor (WHO Grade IV), such as glioblastoma or related types, confirmed by a tissue sample, tested as IDH wild-type, where the tumor has come back or grown after standard first-line treatment. - People whose tumor has ret...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05476939 · Gustave Roussy, Cancer Campus, Grand Paris Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2028
🇩🇰 DK🇫🇷 FR🇪🇸 ES🇸🇪 SE

**Who might be able to join this trial:** - You (or your child) have been diagnosed with a type of brain tumor called DIPG or a related midline brain tumor (DMG), either based on scans and symptoms, a tissue sample (biopsy), or a liquid sample from the blood or spinal fluid. - A tissue sample (biopsy) has been done, o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05477680 · Sklifosovsky Institute of Emergency Care Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇷🇺 RU

Who might be able to join this trial: - People who have a tumor inside the skull (any type) - People who have a cavernoma (a cluster of abnormal blood vessels in the brain) - People who have an arteriovenous malformation (an abnormal tangle of blood vessels in the brain) - People who have had a spontaneous (non-injury-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05480644 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2032
🇺🇸 US

Who might be able to join this trial: - People who have a confirmed diagnosis of a brain tumor that either started in the brain (primary) or spread to the brain from another part of the body (metastatic), confirmed through a tissue sample or medical imaging as appropriate. Who may not be able to join: - No exclusion c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05495295 · Phost'In Therapeutics Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 4 November 2024
🇫🇷 FR🇮🇹 IT

**Who might be able to join this trial:** - People who have been confirmed to have cancer through a tissue or cell sample test. - Depending on which part of the trial a person joins: people with any solid tumour type (dose escalation phase); people with a brain cancer called glioblastoma, or GBM (Cohort 1); people wit...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05521984 · Washington University School of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 March 2031
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a primary brain tumor that has come back, where no curative treatment is available, OR a solid tumor that has returned or stopped responding to treatment, where no curative option exists and at least two lines of prior treatment have been...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05535166 · St. Jude Children's Research Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2035
🇺🇸 US

**Who might be able to join this trial:** - The child must have a suspected or confirmed new diagnosis of a brain tumour called medulloblastoma. - The child must be under 60 months (5 years) of age at the time of joining the study. - During the initial screening stage, the child must be either under 36 months old, or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05535413 · Hunan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have been diagnosed with breast cancer that has come back or spread to other parts of the body, and your cancer has tested negative for HER2 (a specific protein) - You have at least one measurable area of cancer in the brain that is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05545007 · Istituto Clinico Humanitas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who are older than 18 years of age - People who have a solid tumour (a type of cancer that forms a lump or mass) confirmed by tissue testing or imaging scans - People for whom doctors have recommended surgery to remove one brain metastasis (a cancer growth that has sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05553899 · Sheffield Children's NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with, or are suspected of having, a cancerous brain tumour that needs treatment - People where the medical team is uncertain, based on standard MRI scans, whether the tumour has come back after previous treatment - People who are expected to live fo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05554302 · Baptist Health South Florida Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard oncology scale called ECOG 0–3 (confirm with trial site) - People who have been diagnosed with brain metastases (cancer tha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05555550 · Children's Hospital of Philadelphia Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a low-grade brain tumour (Grade I or II) located in the brainstem or the upper part of the brain, confirmed by a biopsy (or, for those with a condition called NF1, by the typical appearance of the tumour on scans). - People whose tumour measure...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05559853 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 September 2027
🇺🇸 US

Who might be able to join this trial: **Healthy volunteers (for certain parts of the study):** - You are 18 years old or older - You are able to understand and agree to participate in the study - You have not been diagnosed with cancer **Patients (for certain parts of the study):** - You are 18 years old or older - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05564949 · Attikon Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2025
🇬🇷 GR

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People whose general health and ability to carry out daily activities meets a minimum level, as measured by a standard medical scoring system called the Karnofsky Performance Score (a score of 50 or above is required — confirm with tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05565118 · Case Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have brain scan (MRI) findings that appear to show a high-grade glioma (a fast-growing type of brain tumour, WHO Grade 3 or 4, including a type called GBM), or people who have already been diagnosed with this type of brain tumour and are having surgery to remove a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05565326 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇭 CH

**Who might be able to join this trial:** - People who have signed an informed consent form before any trial procedures begin - People who have a confirmed diagnosis of glioblastoma (a type of brain tumour), confirmed through a tissue sample - People for whom doctors have recommended a course of fractionated radiation...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05576103 · Jona Hattangadi-Gluth Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You are generally able to carry out normal daily activities with at least some level of independence (confirm with trial site) - Your doctors expect you to live for at least 1 year or more - You have a primary brain tumor and are scheduled to re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05577091 · Beijing Tiantan Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 70 years old (inclusive). - People who have a history of glioblastoma (a type of brain tumour) and have been diagnosed with a recurrence of glioblastoma, with some tumour remaining after surgery or biopsy performed at Beijing Tiantan Hospital. - Pe...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05588141 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a type of brain tumour called diffuse glioma (WHO grades 2–4), confirmed by tissue testing at the NCI Laboratory of Pathology. - People whose tumour has a specific genetic change called an IDH1 or IDH2 mutation, confirmed by a specific genetic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05595577 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 85 years old - People who have been diagnosed with stage I–IV Hodgkin's or non-Hodgkin's lymphoma, or stage I–III breast cancer - People who are expected to receive certain cancer treatments, including specific types of chemotherapy (such as anthracycli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05609994 · Katy Peters, MD, PhD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People whose brain tumor tissue tests positive for a specific genetic change called IDH1R132H - People with a Grade 2 or Grade 3 glioma (a type of brain tumor) that has come back or grown, with a certain amount of tumor visible on scans that does no...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05622409 · National Health Research Institutes, Taiwan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

**Who might be able to join this trial:** - People who have been diagnosed with, or are suspected to have, a type of adult brain tumour called an adult-type diffuse glioma (including glioblastoma, astrocytoma, or oligodendroglioma, as classified by World Health Organization guidelines) - People who are willing to prov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05629702 · University of Birmingham Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of brain tumour called glioblastoma (GBM) that has certain molecular features — specifically, MGMT promoter methylation and IDH wild type — confirmed by a laboratory test. - People whose brain tumour has come back for the f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05653622 · Centre Paul Strauss Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 years or older who are not suitable for a standard intensive treatment protocol (called the STUPP protocol), and who fall into one of two groups: - **Group 1:** People aged 18–70 who cannot have surgery, have a functioning level score (Karnofsky Index) of 50...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05653635 · Centre Paul Strauss Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed with glioblastoma (a type of brain tumour), Grade IV, confirmed by a tissue sample (biopsy or surgery) - You are reasonably active and able to care for yourself, with a performance level rated 0, 1, or 2 (a standard scale do...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05659524 · Lori Wood Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You are an adult who is scheduled to have endoscopic (minimally invasive, through the nose) surgery to remove a pituitary tumor, including non-functioning adenoma, acromegaly-related tumors, prolactinoma, or Rathke's cleft cyst - You are between 18 and 85 years old - You spea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05660369 · Marcela V. Maus, M.D.,Ph.D. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** *General criteria that apply to all groups:* - People aged 18 or older. - People whose cancer is not located only in the lower back part of the brain (posterior fossa) or only within the spinal cord itself. - People who have recovered from most side effects of previous cancer...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05669820 · Peter Siesjö Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇸🇪 SE

Who might be able to join this trial: - People who have been diagnosed with glioblastoma or grade 4 astrocytoma, confirmed by a pathology (laboratory) test - People between the ages of 18 and 75 years old - People who have had surgery to remove (resect) the tumour - People who are scheduled to receive radiation and che...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05683808 · University of Vermont Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a high-grade brain tumour (specifically a WHO grade 4 malignant glioma, such as glioblastoma or astrocytoma), confirmed by a recent biopsy or surgery. - People aged 18 or older. - People who have a reasonable level of physical functioning,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05686798 · Henry Ford Health System Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been previously diagnosed with a high-grade brain tumour called glioblastoma or anaplastic astrocytoma, and whose brain scans show signs that the tumour has come back or grown - People who are 18 years of age or older and are able to give informed consent and...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05692635 · Wake Forest University Health Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older. - People diagnosed with a specific type of lung cancer (non-squamous) that is locally advanced, classified as stage IIIA, IIIB, or IIIIC according to standard cancer staging guidelines. - People whose lung cancer tissue analysis shows a mi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05700721 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who have cancer that has spread to the brain, and whose cancer is one of the following types: advanced BRCA1 or BRCA2 gene-mutated cancer, advanced cancer with certain DNA repair gene changes (but not BRCA1/2), advanced small...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05708352 · Cedars-Sinai Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been recently diagnosed with glioblastoma (a type of brain tumour), with the diagnosis confirmed by a tissue test within the last 2 months - People who have not yet started standard chemotherapy or radiation treatment for glioblasto...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05717712 · Capital Medical University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 4 January 2025
🇨🇳 CN

**Who might be able to join this trial:** - Parents or the patient (depending on age) have given written consent to participate. - The patient is able to follow all the study procedures, in the opinion of the study doctor. - The patient is between 1 and 18 years old. - Female patients who are able to become pregnant h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05727605 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇧🇪 BE

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with a primary brain tumour or a tumour at the base of the skull - People whose tumour is suitable for a standard course of radiation therapy (using either conventional X-ray-based or proton-based radiation) **Who may not be ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05734560 · Darell Bigner Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of joining the study - People who have been newly diagnosed with a specific, high-grade brain tumour (called glioblastoma, or GBM, WHO grade 4, IDH wildtype, MGMT unmethylated) that still shows some visible disease on a brain scan after in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05755399 · University of Minnesota Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - People who are able to understand and agree to participate in the study (give informed consent) - People who are scheduled for and attending brain surgery - People whose surgery will be performed under general anesthesia (fully asleep during the procedure) - People whose surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05756985 · Baptist Health South Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have brain scan (MRI) results showing what appears to be a high-grade brain tumour, and who are willing to have surgery if the initial tissue test during the operation confirms it is glioblastoma or gliosarcoma - People who have already been diagnosed with gliobla...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05762419 · Columbia University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Children and young people between the ages of 4 and 21 years old. - People who have been diagnosed with a specific type of brain tumour called Diffuse Midline Glioma, confirmed either by brain scan or by laboratory testing of tumour tissue, and whose disease has shown signs...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05765643 · The Hong Kong Polytechnic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
Hong Kong

**Who might be able to join this trial:** - Parents or caregivers of a child with complex medical needs, where the child is between 2 and 18 years old - People who own and use a smartphone - People who can speak and read Chinese - People who live at home together with their child **Who may not be able to join:** - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05768087 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇩🇰 DK

Who might be able to join this trial: - People who have been newly diagnosed with a specific type of brain tumour called glioblastoma (GBM), confirmed using the latest medical classification system (WHO 2021). - People who have undergone the safest possible level of surgery to remove the tumour — any amount of surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05768490 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with non-small cell lung cancer, confirmed through a tissue or cell sample test - People who have been newly diagnosed with a small number of brain metastases (cancer that has spread to the brain) — specifically fewer than 5 spots in the brain,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05769010 · Henan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with advanced breast cancer that has been confirmed by lab testing to be HER2-positive or HER2-low - You have at least one measurable tumor in the brain that has not yet been treated locally (for example, not yet treated...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05769660 · BeyondBio Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2026
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 19 years or older at the time of agreeing to participate - People who have been diagnosed with glioblastoma (GBM) according to World Health Organization criteria - People whose GBM has come back or gotten worse after receiving the standard initial treatment - Peo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05775458 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇮🇹 IT

Who might be able to join this trial: - You are an adult with a brain lesion that doctors suspect may be a type of brain tumor called GBM (glioblastoma), and you are scheduled for surgery to remove as much of the tumor as possible, followed by radiation therapy and chemotherapy. - You are able to understand the study i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05789394 · Mayo Clinic Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 24 July 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older - People whose general health and ability to function meets a minimum level, as measured by a standard scale called the Karnofsky Performance Scale (score of 60 or above) (confirm with trial site) - People who have previously been diagnosed with a specific...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05804669 · Crinetics Pharmaceuticals Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 years or older (male or female) - People who have long-term, ongoing ACTH-dependent Cushing's syndrome (a hormonal condition where the body produces too much cortisol due to excess ACTH hormone) - People whose Cushing's syndrome has been actively causing sympto...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05831631 · Pietro Mortini, MD, Prof. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇮🇹 IT

Who might be able to join this trial: - You must be an adult aged 18 or older - You must be able to understand and agree to take part in the trial yourself - You must have a brain tumor, either one that started in the brain or one that has spread to the brain from elsewhere in the body - You must need brain surgery or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05857969 · Florida International University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 22 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 21 years or younger at the time of joining, of any gender, race, or ethnicity - People with a suspected or confirmed cancer that has come back or has not responded to previous treatment - People who are scheduled to have, or have recently had, a biopsy or surgical...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05859334 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 23 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - You must have a type of brain tumor called an IDH-wildtype glioma (grade 2, 3, or 4), confirmed by a tissue sample test - Your tumor must have a specific genetic change called an FGFR-TACC gene fusion, found through an approved genetic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05859659 · Yaou Liu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a type of brain tumour called glioma, confirmed through tissue testing - People who have a complete set of MRI scans with clear, usable images - People who have signed a form agreeing to take part in the study Who may not be able to join: - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05864274 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - People who have been recently diagnosed with a gynecologic cancer (such as uterine, cervical, ovarian, primary peritoneal, vulvar, or vaginal cancer) and are currently receiving chemotherapy - People who own a smartphone or tablet that is capable of downloading a cognitive traini...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05864534 · Northwestern University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2031
🇺🇸 US

**Who might be able to join this trial:** - You have been recently diagnosed with a specific type of brain tumor called glioblastoma, confirmed by a lab test, with a particular genetic profile (called "IDH wild-type") - Your tumor has a specific genetic marker called "MGMT unmethylated" (a lab test your doctor can che...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05866432 · Medical University of Vienna Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 23 May 2026
🇦🇹 AT

**Who might be able to join this trial:** - People who have been diagnosed with breast cancer confirmed by laboratory testing of tissue samples - People whose breast cancer is "triple-negative," meaning the cancer tests negative for oestrogen receptors, progesterone receptors, and HER2 protein (less than 10% of tumour...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05868928 · Asan Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇰🇷 KR

**Who might be able to join this trial:** - People who have had a type of precise brain radiation treatment called stereotactic radiosurgery (SRS — including Gamma Knife or CyberKnife) for cancer that has spread to the brain - People with between one and ten newly diagnosed brain tumours that are suitable for this typ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05872347 · Shanghai Pharmaceuticals Holding Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily, fully understand the study, and are willing to sign a consent form. - People who are generally well enough to carry out daily activities with little to no limitation (based on a standard fitness scale scored 0 or 1). - People with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05879250 · Northwestern University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 27 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been newly diagnosed with a specific type of brain tumor called glioblastoma (GBM), confirmed by a tissue sample (biopsy or surgery), with specific genetic features called "IDH wild-type" and "MGMT unmethylated" (confirm with trial site for testing details) - You ar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05879367 · Orbus Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of brain tumour — either a grade 4 glioblastoma (GBM) with a particular genetic profile (IDH-wildtype), or a grade 3 astrocytoma with certain genetic markers — classified according to the 2021 World Health Organization system. -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05902169 · CarThera Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 28 January 2028
🇦🇹 AT🇧🇪 BE🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇪🇸 ES +3 more

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by tissue testing, with a specific genetic result showing no IDH mutation - People who have already received first-line treatment that included brain surgery or a biopsy, plus a course of ra...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05904119 · European Organisation for Research and Treatment of Cancer - EORTC Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2027
🇦🇹 AT🇧🇪 BE🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL +3 more

**Who might be able to join this trial:** - People who have signed a written consent form before joining the trial, as required by international research guidelines. - People whose glioblastoma has come back or progressed for the first time after standard chemotherapy and radiation treatment, with that progression hap...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05911230 · University Hospital, Basel, Switzerland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇨🇭 CH

Who might be able to join this trial: - People who have been diagnosed with glioblastoma (a type of brain tumour) or brain metastasis (cancer that has spread to the brain) confirmed through laboratory testing of tissue, where the tumour appears to have grown or returned on a standard MRI scan after completing first-lin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05917145 · Mayo Clinic Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 May 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed (confirmed by tissue testing) with one of the following brain tumours: Glioblastoma (IDH-wildtype), or a Grade 3 or 4 astrocytoma with an IDH1 or IDH2 mutation (based on 2021 WHO classification) - People whose tumour i...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05921786 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - Adults over 18 years old who have been diagnosed with a brain disease (either newly diagnosed or returned after previous treatment) and are considered suitable for, and willing to have, surgery to remove the affected tissue. Who may not be able to join: - People who are unable t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05929495 · University of Milano Bicocca Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been newly diagnosed with a specific type of brain tumour called glioblastoma (GBM, WHO grade IV, IDH wild type) and have had surgery to remove or reduce the tumour - People who have had a specific gene marker on the tumour (called MGMT methylation status) tested...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05941234 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with a type of brain tumor called glioblastoma in the upper part of the brain, based on imaging scans (such as an MRI), OR your glioblastoma has come back for the first time after previously being confirmed by a tissue biopsy - You are scheduled to hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05947045 · St. Jude Children's Research Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are starting radiation treatment for a brain tumor - People who are between 8 and 22 years old at the time of joining the trial - People whose primary language is English or Spanish - People (and one of their parents) who are willing to take part and give their agr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05947149 · CNAO National Center of Oncological Hadrontherapy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 September 2025
🇮🇹 IT

Who might be able to join this trial: **Cohort A ("Survivors" group):** - People who have had head and neck, skull base, or brain tumours and have been monitored for at least 5 years with no signs of the disease getting worse - People who are able to give their own consent to participate **Cohort B (Treatment group):...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05954858 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who are scheduled to have surgery to remove a known or suspected brain tumour called glioblastoma (GBM) - People with a general health and functioning level of 70% or higher on a standard medical scale called the Karnofsky Perf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05956821 · University of Miami Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed tissue diagnosis of a relapsed or returning brain tumour — specifically glioblastoma multiforme (GBM), anaplastic astrocytoma, fibrillary astrocytoma, pilomyxoid astrocytoma, oligodendroglioma, or anaplastic mixed oligoastrocytoma — or a radiologi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05968053 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

"Who might be able to join this trial: - Adults between 18 and 80 years of age - People who are scheduled to undergo any type of brain or nervous system surgery (neurosurgery) Who may not be able to join: - People who do not wish to take part in the trial Important: Always verify eligibility with the trial site direc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05971758 · University of California, Los Angeles Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People with Cushing's syndrome confirmed to be coming from the pituitary gland, shown by consistently high cortisol levels in urine tests, plus normal or raised ACTH hormone levels in the blood, AND either a pituitary tumour larger th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05976490 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 September 2026
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who are patients at the Massachusetts General Hospital Cancer Center - People who have been diagnosed with a primary malignant brain tumor within the last 6 weeks - People who are able to speak and read in English Who may not be able to join: - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05977803 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 February 2029
🇫🇷 FR

Who might be able to join this trial: - Adults aged over 18 years - People who have been diagnosed with primary lung cancer confirmed by a tissue sample (biopsy) - People who have brain metastases (cancer that has spread to the brain), whether confirmed by tissue sample or not - People whose brain metastases have been...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05978557 · UNC Lineberger Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

Who might be able to join this trial: - You are willing and able to sign a consent form agreeing to take part in the study and allowing your personal health information to be used (for children, a parent or guardian can provide this consent) - You have been diagnosed with a tumor located in the brain or spinal cord (ce...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05979064 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who are scheduled to have surgery to remove a known or suspected brain tumour called glioblastoma (GBM) - People whose general health and functioning is rated at 70% or above on a standard medical scoring scale (confirm with tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05984888 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with Stage II, III, or IV breast cancer that is hormone receptor-positive (a type that responds to hormones) - People who are post-menopausal — meaning their periods stopped at least one year ago, or they are taking medication to suppress their...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05990244 · Shengjing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: - People who are older than 18 years of age - People who have a relatively good level of physical functioning, as assessed by a standard medical scale called the Karnofsky performance status (score above 60) (confirm with trial site) - People who are willing and able to provide wri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05990556 · First Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with glioblastoma (a type of brain tumour) based on imaging scans or a needle biopsy tissue sample - People who have not previously had radiotherapy, chemotherapy, or any other treatments for tumours in the brain - People who have no medical reasons...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06001073 · First Affiliated Hospital Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are regularly attending and being followed up at the relevant medical department - People who have been diagnosed with at least one of the following conditions: coronary artery disease, an abnormal heart rhythm (arrhythmia), heart valve disease, aortic dissection,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06001281 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - Adults diagnosed with glioblastoma (a type of brain tumour) that has come back, and where the tumour has a specific characteristic called "IDH wildtype" - The tumour has returned after completing the standard first treatment, which involves both radiation therapy and chemothe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06011109 · Aveta Biomics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of a high-grade brain tumour (grade III or IV glioma, including glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, or H3K27M mutant glioma) that has continued to grow or returned after treatment with bevaciz...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06015802 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a pituitary neuroendocrine tumour (a type of growth on the pituitary gland) based on medical imaging, whether or not the tumour produces hormones (confirmed by hormone testing) **Who may not be able to join:** - People whose previous tissu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06016452 · Tata Memorial Centre Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2025
🇮🇳 IN

Who might be able to join this trial: - People who have been diagnosed with a type of brain tumour called diffuse glioma, confirmed through a tissue sample (biopsy). - People who have imaging results showing radionecrosis (a type of tissue damage that can occur after radiation treatment to the brain) along with new or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06036394 · Tata Memorial Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇮🇳 IN

Who might be able to join this trial: - People who had a brain or spinal cord (central nervous system) tumour that was treated with radiation therapy at Tata Memorial Centre (TMC) between January 2010 and December 2022. Who may not be able to join: - People whose radiation therapy was carried out at a hospital or cent...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06039709 · Shayan Moosa, MD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People with suspected returning glioblastoma (a type of brain tumour) that can be clearly seen and measured on imaging scans, with at least one area of the tumour that shows up with contrast dye, sized between 2 cm³ and 20 cm³ - People whose tumour is located in a part of th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06048094 · Baptist Health South Florida Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2032
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cancer that has spread to the brain, confirmed by imaging scans. - People whose brain tumours (however many there are) are all 2 cm or smaller in size. - People whose medical team has already planned for them to receive a type of targeted...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06051240 · Region Stockholm Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2030
🇸🇪 SE

**Who might be able to join this trial:** - Be older than 5 years of age - Be younger than 18 years old at the time they received radiation therapy - Have received radiation treatment to the brain or spine for a brain tumor within the last 7 years - Be using an adequate form of birth control throughout the entire treat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06055790 · University of Arizona Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been clinically suspected of having, or diagnosed with, one or more tumours that have spread to the brain (brain metastases) - People aged 18 years or older - People with a known history of cancer - People who have had a brain MRI scan within the past 2 month...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06056115 · Hebei Medical University Fourth Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 April 2025
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with stage IV lung adenocarcinoma (a type of lung cancer that has spread to other parts of the body) that has been confirmed by tissue or cell testing, and where surgery or radiotherapy to fully remove the cancer is not possible - People who have cancer that has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06059690 · Jonsson Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2027
🇺🇸 US

Who might be able to join this trial: - People who are over 18 years old - People who have been newly diagnosed with glioblastoma (a type of brain tumour) or whose glioblastoma has come back, and whose doctors have recommended surgery to remove the tumour Who may not be able to join: - People for whom MRI or FDG PET s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06069726 · Duke University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a specific type of brain tumour called glioblastoma (GBM, IDH-wildtype), confirmed by a tissue test - Your brain tumour has come back for the first or second time after you received radiation therapy and a chemo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06072807 · Weill Medical College of Cornell University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - People who have an active diagnosis of ER+ (estrogen receptor positive) breast cancer, confirmed by biopsy, and who have brain metastases (cancer that has spread to the brain) that are either new or have come back, confirmed by biopsy or suspected based on an MRI scan - People wh...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06087393 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 October 2026
🇺🇸 US

Who might be able to join this trial: - People who have a growth or abnormality in the brain that requires surgery to remove it - People scheduled for surgery to remove a type of brain tumor that is likely to be high grade (fast-growing or aggressive) and invasive - People scheduled for surgery to remove other types of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06090903 · Jonsson Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 April 2027
🇺🇸 US

Who might be able to join this trial: - People who are older than 18 years of age - People who have been newly diagnosed with, are suspected of having, or have a returning form of a brain tumor called glioblastoma (GBM), where the tumor is actively growing (shown by enhancement on scans), is larger than 1.5 mL, and sur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06099743 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who are patients at the Massachusetts General Hospital Cancer Center - People who have been diagnosed with a cancerous brain or spinal cord tumor within the last 6 months - People who speak English Who may not be able to join: - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06102525 · Rznomics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇰🇷 KR

Who might be able to join this trial: - Adults (male or female) aged 18 or older - People with a brain tumour confirmed by laboratory testing to be a grade 4 astrocytoma or glioblastoma (GBM), as defined by the 2021 WHO brain tumour classification guidelines - People whose tumour tests positive for a specific protein c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06113705 · Istituto Clinico Humanitas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 or older, of any sex or racial background. - People who have been diagnosed with a specific type of brain tumour called glioblastoma multiforme (confirmed by tissue testing or by medical history, symptoms, and brain scan results that strongly point to this diagnosi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06117930 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 December 2029
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who are having surgery to remove a tumor in the brain or spinal cord (central nervous system) - People without a brain or spinal cord tumor who are taking part as a comparison group (controls) may also be eligible Who may not be able to join: - People und...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06118723 · Jasper Gerritsen Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇧🇪 BE🇩🇪 DE🇳🇱 NL🇨🇭 CH🇺🇸 US

Who might be able to join this trial: - People aged 18 to 90 years old - People whose MRI scan has been assessed by a neurosurgeon and shows a high-grade brain tumour (classified as WHO grade III or IV) - People who are able to provide written agreement to take part in the trial Who may not be able to join: - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06136611 · The Christie NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 September 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who are older than 35 years of age - People of any sex (male or female) - People who have recently been diagnosed with glioblastoma (a type of brain tumour) based on a scan - People who are largely able to carry out daily activities with little to no limitation (as as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06136884 · A2A Pharmaceuticals Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 28 January 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older. - People with a confirmed advanced or spreading solid tumour (not melanoma) that has a TP53 gene mutation or loss, and whose cancer has come back or stopped responding to at least one previous systemic treatment. - People with prostate cancer that has spr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06140719 · xCures Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People diagnosed with diffuse midline glioma (a type of brain or spinal cord tumor) according to the 2021 World Health Organization classification, including a specific type called diffuse intrinsic pontine glioma (DIPG). If there is no confirmed tissue diagnosis, people with a h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06140875 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 May 2029
🇩🇪 DE

**Who might be able to join this trial:** - You have been recently diagnosed with glioblastoma (a type of brain tumour), confirmed by a tissue sample and classified according to standard medical guidelines - You are between 18 and 70 years old and are generally able to carry out most daily activities with minimal limi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06159335 · University of Wisconsin, Madison Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People who are able and willing to give their formal consent to take part in the study - People who have been diagnosed with brain metastases (cancer that has spread to the brain) and have at least one visible affected area showing up on a bra...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06161519 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 November 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a primary brain or spinal cord (central nervous system) tumour, confirmed by a pathology report, that fits one of the specific tumour types listed for each study group (cohort). - People in the Phase I group: those with any primary brain or spi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06164314 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have a brain tumour (glioma) located in the temporal region of the brain and are scheduled for planned brain surgery - You are 18 years of age or older - You are willing and able to give written consent to take part in the trial **Who may not be able to join:** - You hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06176066 · University of California, Los Angeles Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who are able to give written consent to participate, and who are able to follow the study requirements - People who have a good general level of functioning, as measured by a standard medical scale called the Karnofsky Performance Scale (scor...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06176261 · Sarah Sammons, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with metastatic breast cancer that has been confirmed by a pathologist to be HER2-negative, based on 2018 testing guidelines. - People whose metastatic disease has been confirmed by imaging (such as a scan). - **For Groups A and B:** People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06177964 · Darell Bigner Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of joining the study - People who have been confirmed by laboratory tissue analysis to have a recurring glioblastoma brain tumour (a specific high-grade brain cancer) that is located in the upper part of the brain - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06183983 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇳🇱 NL

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with a specific type of brain tumour called IDH-wildtype glioblastoma, confirmed through laboratory testing of tissue removed during surgery or biopsy - People who have been referred to a radiotherapy outpat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06185686 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇺🇸 US

Who might be able to join this trial: - People between 8 and 21 years of age (inclusive) - People who have been newly diagnosed with a primary brain tumor of any location or type, and who will be treated with proton radiation therapy - People with a life expectancy of at least one year - People who are able to understa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06186401 · Hideho Okada, MD, PhD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older with a brain tumour diagnosis of glioblastoma (GBM) that tests positive for a specific protein marker called EGFRvIII, confirmed by an approved laboratory test - People with a performance status score showing they are reasonably functional in daily life (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06193759 · Children's National Research Institute Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 29 December 2030
🇺🇸 US

**Who might be able to join this trial:** **General eligibility (applies to all participants):** - People who have been diagnosed with certain brain tumors — either a new diagnosis of specific childhood brain tumors (including medulloblastoma, embryonal tumor with multilayered rosettes, pineoblastoma, atypical teratoi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06199479 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years of age - People who are willing to take part in the study and attend all required appointments and assessments - People who have previously been treated for a brain tumor, have a new suspicious finding on a brain scan, and are being considered fo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06203496 · University Hospital, Caen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇫🇷 FR

Who might be able to join this trial: - People who are adults (18 years of age or older) - People diagnosed with a grade 4 diffuse glioma (a specific type of aggressive brain tumour) - People who had their brain surgery performed at the neurosurgery department of Caen University Hospital - People who are enrolled in a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06211257 · Centre Oscar Lambret Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇫🇷 FR

Who might be able to join this trial: - People diagnosed with sarcoma (a type of cancer) affecting soft tissues or internal organs - People whose cancer cannot be removed by surgery and has either spread to other parts of the body or has grown significantly in a local area - People for whom a doctor has recommended tre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06220552 · Fifth Affiliated Hospital, Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by tissue testing, where the cancer has come back either based on imaging scans or further tissue testing - People aged 18 or older - People who are at least 12 weeks past completing radiati...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06221553 · Chulalongkorn University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2026
🇹🇭 TH

**Who might be able to join this trial:** - People who have been diagnosed with diffuse intrinsic pontine glioma (a type of brain tumour in the brainstem) at any point after finishing standard radiation treatment - Children and young people between 1 and 18 years old - Both males and females are eligible - People who...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06222138 · Institut Claudius Regaud Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇫🇷 FR

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of joining the study - People who have been recently diagnosed with glioblastoma (a type of brain tumour) for the first time - People for whom a treatment plan involving radiation therapy, chemotherapy, and TTFields (a devic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06229483 · Stephen Lownie Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 January 2027
🇨🇦 CA

Who might be able to join this trial: - Adults between 18 and 80 years of age (either male or female) - People who are already scheduled to have a craniotomy (a type of brain surgery) to remove a tumor - People who have given written consent to participate, or whose legal decision-maker has given written consent on the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06231186 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand the research, are willing to take part, and can sign a consent form - People with a general health status rated as reasonably functional (on a standard scale used by doctors to measure how well a person can carry out daily activities — confirm wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06238882 · Instituto Nacional de Cancerologia de Mexico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 December 2026
🇲🇽 MX

**Who might be able to join this trial:** - People diagnosed with advanced non-small cell lung cancer (either at an advanced stage from the start, or cancer that has come back), confirmed by laboratory testing of tissue or cell samples. - People who have cancer that has spread to the brain and are being considered for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06243003 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People whose general physical functioning is rated as reasonably good by their doctor (on a standard scale used in cancer care, scored 0–2) - People who have been diagnosed with small cell lung cancer, confirmed through a tissue or cell sample - People who have had a full se...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06254326 · University of Florida Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 years or older, of any gender. - Tumor tissue collected during the screening process is available for testing. - People who have been diagnosed with a specific type of returning or growing brain tumor called IDH-mutant 1p/19q co-deleted Oligodendroglioma (Grade 2 o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06264388 · Ashish Shah Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2034
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 75 years old. - People who have a laboratory-confirmed diagnosis of high-grade glioma (a type of brain tumour) that has come back or grown for the first or second time. - People whose brain tumour is either able to be surgically removed or not able to be su...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06273176 · Erasmus Medical Center Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇧🇪 BE🇩🇪 DE🇳🇱 NL🇨🇭 CH🇺🇸 US

Who might be able to join this trial: - Adults aged 18 to 90 years old - People who have a previously diagnosed glioblastoma (a type of brain tumour), classified according to the 2021 World Health Organisation brain tumour guidelines, that has come back after earlier treatment - People whose tumour is located in or clo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06280300 · University of Vermont Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older, of any gender. - People who have been diagnosed with brain metastases (cancer that has spread to the brain) that are newly found, confirmed through a tissue sample (biopsy), and originated from a known or suspected solid tumour elsewhere i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06282224 · The First Affiliated Hospital of Xiamen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 January 2025
🇨🇳 CN

Who might be able to join this trial: - People who are considered suitable candidates for a type of minimally invasive surgery performed through the nose using a small camera (transnasal endoscopic surgery). - People who have had specific detailed brain scans — an MRI and a CTA (a type of scan that looks at blood vesse...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06282562 · Amsterdam UMC, location VUmc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2026
🇳🇱 NL

Who might be able to join this trial: - People who feel their physical fitness is lower than it should be, based on their own assessment - People who are at least 18 years old - People who have been diagnosed with a primary brain tumor (a tumor that started in the brain) - People whose disease is currently stable, mean...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06283927 · Jasper Gerritsen Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇧🇪 BE🇩🇪 DE🇳🇱 NL🇨🇭 CH🇺🇸 US

Who might be able to join this trial: - Adults aged 18 to 90 years old - People who have been previously diagnosed with glioblastoma (a type of brain tumour) based on current medical classification standards, and whose tumour has come back, as confirmed by specific medical imaging guidelines called RANO criteria - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06297512 · Iacopo Sardi Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 9 November 2027
🇮🇹 IT

**Who might be able to join this trial:** - You (or your child) have been diagnosed with a specific type of brain tumor (a form of glioblastoma or related high-grade brain tumor) confirmed by laboratory testing, including cases where the tumor has spread or affects multiple areas of the brain - This is a first-time di...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06306118 · Medical University of Graz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇦🇹 AT

Who might be able to join this trial: - You are between 18 and 80 years old - You have been diagnosed with a lesion (abnormal area) in the brain that your doctors have recommended removing through surgery - You are willing and able to give written consent to take part in the study - You are able to safely have an MRI s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06313853 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 April 2027
🇺🇸 US

**Who might be able to join this trial:** *For patients:* - People aged 65 or older - People who have been diagnosed with Alzheimer's disease or a related form of dementia (including vascular dementia, Lewy body dementia, frontotemporal dementia, or dementia of unknown type) - People who have also been diagnosed with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06314607 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2034
🇫🇷 FR

"Who might be able to join this trial: - People aged 18 years or older. - People who have had surgery on a brain lesion, such as a brain tumour (including glioma, primary central nervous system lymphoma, meningioma, or a rare brain tumour), or who are currently being monitored for one of these conditions. - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06315010 · MedSIR Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇦🇹 AT🇩🇪 DE🇪🇸 ES

**Who might be able to join this trial:** - People who are able to understand the study's purpose and have signed a written consent form before any study procedures begin. - People who are 18 years of age or older at the time of signing the consent form. - People who are able to swallow capsules whole, without chewing...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06319027 · ECOG-ACRIN Cancer Research Group Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older. - People whose general health and ability to carry out daily activities meets a minimum level, as measured by a standard medical scale (Karnofsky Performance Status of 60% or higher). - People who have been newly diagnosed with a specific...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06320496 · Union de Gestion des Etablissements des Caisses d'Assurance Maladie -... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇫🇷 FR

Who might be able to join this trial: - Children who have a chronic condition, rare disease, or disability that has led to a reduced ability to exercise - Children who are attending the CMPRE centre for a program focused on returning to physical activity Who may not be able to join: - Children who are younger than 8 y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06322602 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇺🇸 US

Who might be able to join this trial: - There must be clinical signs and scan results suggesting the presence of a brain tumor. - A biopsy of a suspected or previously diagnosed brain tumor must already be planned as part of routine care at Mayo Clinic in Rochester, Minnesota. - The patient must be willing to give info...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06327451 · Tianjin Medical University General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 59 years old (any sex) - People whose MRI scan shows clear evidence of a brain tumour called glioma - People whose brain tumour tissue, tested after surgery, has been classified as Grade 4 Glioblastoma according to the 2021 WHO classification system - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06328686 · Emory University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cancer that has spread to the brain (brain metastases), regardless of where the original cancer started - People who are planned to receive a type of radiation treatment called whole-brain radiation therapy (a version that protects a part o...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06329570 · NaviFUS Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of joining the trial. - People with a body mass index (a measure of body weight relative to height) of 17 or above. - People who have been diagnosed with glioblastoma (a type of brain tumour) that has clearly come back, confirmed by a spec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06330337 · The Third Affiliated hospital of Zhejiang Chinese Medical University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a high-grade brain tumour (confirmed by biopsy), have already had surgery followed by standard radiation and chemotherapy, and scans show the tumour has come back. - You are between 18 and 70 years old (any gender). - If you are taking the steroi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06330870 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 February 2025
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with breast cancer - People who have had curative surgery to remove brain metastases (cancer that has spread to the brain and was treated with an operation aimed at removing it) Who may not be able to join: - People who have had Gamma Knife surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06344130 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a type of brain tumour called glioblastoma or gliosarcoma (either as a first diagnosis or one that developed from a lower-grade brain tumour), confirmed by laboratory testing of tumour tissue. - People aged 18 or older. - People who have a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06352710 · Cantonal Hospital of St. Gallen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇭 CH

**Who might be able to join this trial:** - People aged 18 or older - People who are able to give their own consent to participate - People who are willing to share their health data for up to one year after their surgery - People who own and are able to use a smartphone (Android or iPhone) - People who have the langua...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06353529 · Hamilton Health Sciences Corporation Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 April 2026
🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 years or older - People who are having surgery to remove a pituitary adenoma (a type of non-cancerous brain tumour) through the nose Who may not be able to join: - People who have existing long-term pain conditions that require certain medications, including antid...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06356883 · Université de Sherbrooke Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with glioblastoma multiforme (a type of brain tumour), confirmed by a tissue biopsy. - Your brain tumour has shown signs of growing again on an MRI scan, after you have already been treated with the standard treatment combining radiotherapy and a chem...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06362304 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been clinically diagnosed with a brain tumor - People who are at least 18 years old - People whose tumor tissue can be obtained and examined in a laboratory through surgery or biopsy - People who are able to give their consent to participate and are able to at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06362707 · Helse Stavanger HF Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇳🇴 NO

**Who might be able to join this trial:** - People diagnosed with early Alzheimer's disease — specifically, mild cognitive impairment (Stage 3) or mild Alzheimer's dementia (Stage 4), as defined by the FDA in 2018 - People who have had a brain scan (amyloid PET) or specific lab tests (spinal fluid or blood) showing ab...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06367920 · Bundang CHA Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇰🇷 KR

Who might be able to join this trial: - People aged 20 years old or younger, including healthy individuals and patients, who had imaging examinations (such as brain MRI scans to look into the cause of developmental delay) done at the Department of Rehabilitation Medicine at the relevant hospital between January 2010 an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06377696 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a brain tumor that requires or has required radiation treatment to the head (enrollment may happen during radiation treatment or up to 5 years after it has finished) - People whose general health and ability to fu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06385132 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 August 2026
🇮🇹 IT

Who might be able to join this trial: - People diagnosed with glioblastoma (a type of brain tumour) or head and neck cancer who are receiving a long course of radiotherapy - People receiving radiotherapy as a follow-up treatment after their main cancer treatment (such as surgery) - People receiving a combination of rad...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06389591 · University of Florida Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have been diagnosed with a type of brain tumor called glioblastoma (GBM), confirmed by a lab test using the most current brain tumor classification system. - People whose brain tumor has clearly come back or grown, as shown on a specific...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06401824 · Maastricht University Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form. - People who are generally well enough to carry out light activity and care for themselves (a doctor will assess this using a standard fitness scale). - People with an estimated life expectancy of 12 weeks or m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06410248 · Northwestern University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 12 May 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of brain tumor (grade 2–4 glioma, IDH wild type, or glioblastoma) confirmed through lab testing of tumor tissue - Your brain tumor has come back (recurred) after receiving standard or investigational first-line treatment, such as...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06418594 · Beijing 302 Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are female and aged 18 or older - People whose doctors expect them to live for at least 3 months - People with locally recurrent or metastatic breast cancer that has been confirmed through tissue or cell testing to be HER2-negative (specific test result categories...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06419946 · Vastra Gotaland Region Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 15 December 2031
🇦🇹 AT🇩🇰 DK🇳🇴 NO🇸🇪 SE

Who might be able to join this trial: - People who have been newly diagnosed with a type of brain cancer called glioblastoma or gliosarcoma, with a specific genetic profile called "IDH wild type" - People whose tumor has a particular genetic marker called a "methylated MGMT promoter," which is determined through testin...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06430424 · University Hospital, Bordeaux Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇫🇷 FR

Who might be able to join this trial: - People who are older than 18 years of age - People who had surgery for glioblastoma (a type of brain tumour) — either a first diagnosis or a return of the tumour — at the CHU de Bordeaux hospital between 2005 and 2023 Who may not be able to join: - People who received systemic t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06431685 · Sichuan University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 28 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have been diagnosed with leptomeningeal metastasis (cancer that has spread to the fluid and membranes surrounding the brain and spinal cord), either confirmed through spinal fluid testing or through a combination of medical history...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06443268 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇨🇭 CH

**Who might be able to join this trial:** **Control Group (people without a recent stroke):** - People aged 18 or older - People who have never had a stroke, or whose last stroke was more than 3 years ago - People with little to no lasting disability from any previous stroke (confirm with trial site) - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06444841 · Baylor University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇺🇸 US

**Who might be able to join this trial:** - You are able to show that you understand what the study involves, including its benefits and risks, and that you can leave at any time — or someone can give consent on your behalf. - You have been diagnosed with, or show signs of, mild cognitive impairment (MCI) or dementia,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06465199 · Milton S. Hershey Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2033
🇺🇸 US

**Who might be able to join this trial:** - You must have been **26 years old or younger** at the time your cancer was diagnosed. - You must have one of the following confirmed cancer diagnoses: relapsed or treatment-resistant neuroblastoma, relapsed or treatment-resistant embryonal tumor with multilayer rosettes (ETM...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06468124 · King's College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇬🇧 GB

Who might be able to join this trial: - You have breast cancer that has spread to the brain and your doctor thinks surgery is a suitable option, OR you have breast cancer that has spread to other parts of the body (outside the brain) and you are already having surgery or a biopsy - You are older than 18 years of age W...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06470711 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

Who might be able to join this trial: - Healthy volunteers with no known medical conditions (for one part of the study) - People who have already been enrolled in a related study (IRB 16-002424), including those who have had surgery to remove or sample a brain tumour that was suspected or confirmed to be a glioma (for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06471465 · Institut Cancerologie de l'Ouest Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2028
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with radionecrosis (damage to brain tissue caused by radiation therapy), supported by specific MRI scan findings and nuclear medicine imaging results - People whose symptoms have not improved or have gotten worse despite taking corticosteroid medica...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06474533 · Thomas Hope Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇺🇸 US

**Who might be able to join this trial:** - You have a known or suspected brain tumor (either confirmed or being investigated). - You have already had treatment (such as radiation or surgery) for a brain tumor, and scans suggest the tumor may have come back — this includes returning spread-from-elsewhere tumors, retur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06476093 · The First People's Hospital of Lianyungang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily and agree to follow the study requirements by signing a consent form. - People who have been confirmed by tissue or pathology testing to have non-small cell lung cancer (a type of lung cancer) that has stopped responding to treatmen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06496971 · NaviFUS Corporation Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇹🇼 TW

**Who might be able to join this trial:** - People aged 18 or older at the time of joining the study. - People with a body mass index (a measure of body weight relative to height) of 17 or above. - People who have been diagnosed with glioblastoma (a type of brain cancer) that has clearly come back, as shown on a contr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06501378 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2025
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older - People whose general health and ability to carry out daily activities meets a minimum threshold, as measured by a standard medical scoring tool called the Karnofsky Performance Scale (score of 70 or above) (confirm with trial site) - People whose lung ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06501391 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have a reasonable level of general health and ability to carry out daily activities (based on a standard scoring system your doctor uses) - Genetic testing of your cancer has come back negative for certain specific gene changes (called E...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06501521 · The Institute of Molecular and Translational Medicine, Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇿 CZ

**Who might be able to join this trial:** - People who are adults (18 years or older) - People who have been diagnosed with a brain tumor **Who may not be able to join:** - People who have another type of cancer in addition to a brain tumor - People who have an inflammatory disease (confirm with trial site for which s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06506578 · University Hospital, Bordeaux Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇫🇷 FR

Who might be able to join this trial: - People who are older than 18 years of age - People who have a non-cancerous (benign) brain tumour - People whose brain tumour is being treated with a standard course of radiation therapy, given in small daily doses of 1.8 to 2 Gray per session Who may not be able to join: - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06510283 · Beijing Tongren Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 14 years or older, of any sex - People whose autoimmune encephalitis symptoms started no more than 9 months before joining the trial - People diagnosed with autoimmune encephalitis, meaning they had a rapid onset (within 3 months) of at least four of these six sy...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06533163 · BioTex, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇩🇪 DE

Who might be able to join this trial: - The person is at least 18 years old. - The person has had surgery to remove as much of a glioblastoma (a type of brain tumour) as safely possible, and is able to receive standard radiation therapy (unless there is a medical reason not to, or the person declines). - The person has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06551909 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with Glioblastoma (a type of brain tumour) - People whose general health and ability to carry out daily activities falls within an acceptable range, as assessed by their doctor at the first visit - People whose tumour has been assessed by the neuros...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06553235 · Aarhus University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇩🇰 DK

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have finished their main breast cancer treatment between 1 and 5 years ago (ongoing hormone/endocrine therapies are still allowed) - People who have significant sleep difficulties, measured either by scoring above 10 on a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06556563 · NovoCure GmbH Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 1 April 2029
🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇯🇵 JP🇵🇱 PL +4 more

**Who might be able to join this trial:** - You (or your legal representative) have agreed to take part and signed a consent form. - You are 18 years of age or older at the time of signing the consent form. - You have been newly diagnosed with a type of brain tumour called glioblastoma (GBM), based on the latest medic...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06558214 · University of Florida Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 18 years old. - People who have been diagnosed with a specific type of brain tumour called recurrent or progressive glioblastoma (WHO Grade IV, IDH wild-type) or a related tumour called astrocytoma (WHO Grade IV) that has come back or continued to gro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06560372 · University Hospital Center of Martinique Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 November 2028
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older - People who are hospitalised at the Martinique University Hospital for treatment or monitoring of a moderate or severe traumatic brain injury (a serious head injury, measured by a standard medical score of 13 or below at the time of first treatment)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06584110 · The University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
Hong Kong

Who might be able to join this trial: - People who have a confirmed diagnosis of dementia and score between 8 and 19 on a cognitive assessment called the HK-MoCA, which indicates mild to early moderate dementia - Family caregivers who live in the same home as the person with dementia - Family caregivers who consider th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06584123 · University of Cambridge Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 September 2026
🇬🇧 GB

Who might be able to join this trial: - People who are willing and able to give their informed consent to take part in the study - People aged 18 or older, of any gender - People who have a suspected pituitary adenoma (a growth on the pituitary gland in the brain) based on symptoms, blood test results, and/or medical i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06584448 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign and date a consent form agreeing to take part - You are willing to follow all study procedures and be available for the full length of the study - You are a male or female in good general health, between 18 and 55 years old - You are able to r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06585527 · Beijing Neurosurgical Institute Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2026
🇨🇳 CN

Who might be able to join this trial: - People who have voluntarily agreed to participate and signed a consent form. - People aged 18 to 65 years old, of any gender. - People who had surgery to fully remove a high-grade brain tumour, followed by standard radiation or chemotherapy, with no signs of the tumour returning...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06595186 · JenKem Technology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old (male or female) - People who have been newly diagnosed with glioblastoma (a type of brain tumour), confirmed by a scan or tissue test, where at least 80% of the tumour was surgically removed - People who have completed a combined chemother...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06598046 · Henan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with invasive breast cancer that has spread to other parts of the body (metastatic), confirmed by tissue or cell testing, or by physical or imaging examination - People whose breast cancer has been confirmed as "triple...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06598787 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form and follow the study requirements - Any gender is welcome to apply - You are 18 years old or older - You have been diagnosed with glioblastoma (a type of brain cancer) that has come back after standard treatment, confirmed by a tissue s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06599879 · Institut Claudius Regaud Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2030
🇫🇷 FR

**Who might be able to join this trial:** - You received radiation treatment (either to part of the brain or the whole brain and spine) for a brain tumour where radiotherapy was part of the main treatment plan - Your child has one of these tumour types: ependymoma, medulloblastoma, malignant germ cell tumour, craniopha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06607029 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are scheduled to have brain surgery (a craniotomy) to remove or treat a tumour in the upper part of the brain, performed under general anaesthetic - People aged between 18 and 65 years old - People whose overall physical health has been assessed by an anaesthetist...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06613841 · Abramson Cancer Center at Penn Medicine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have a newly found brain mass (a growth inside the brain tissue) that a specialist radiologist at Penn believes is consistent with glioblastoma (an aggressive type of brain tumour) - People who have a confirmed past diagnos...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06620380 · University of Zurich Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇭 CH

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form, of any gender - People whose general health and ability to function meets a minimum level as measured by a standard medical scoring tool (Karnofsky performance status of 60 or above — confirm with trial site) -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06623565 · Amsterdam UMC, location VUmc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 or older - People who have recently been suspected, based on clinical assessment and brain scans, of having a specific type of aggressive brain tumor (IDH-wildtype glioblastoma or a high-grade IDH-mutant astrocytoma) - People whose tumor shows uptake on a speci...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06624371 · Emory University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** *Group 1 (Newly diagnosed patients):* - You have been newly diagnosed with a specific type of childhood brain tumor (pediatric high-grade glioma, diffuse midline glioma, or diffuse intrinsic pontine glioma), confirmed by biopsy or MRI scan - You weigh more than 10 kg (about 22...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06625684 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 December 2029
🇺🇸 US

Who might be able to join this trial: - People who are at least 18 years old - People who have a confirmed diagnosis of glioblastoma multiforme (GBM) or a grade 4 brain tumor, confirmed through laboratory testing - People who have a working email address and are available for follow-up contact - People who are willing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06630260 · Institute of Cancer Research, United Kingdom Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2029
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of advanced brain tumour (Grade 4 glioblastoma or related Grade 4 brain tumours confirmed by tissue testing), as classified under medical guidelines from 2016 or 2021. - People who have agreed to be part of the Minderoo Pre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06636162 · Washington University School of Medicine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 17 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a new brain tumour suspected to be a glioma based on imaging, or a confirmed return of a glioma with a specific genetic change called an IDH mutation — with two groups: one for lower-grade gliomas (Arm A) and one for higher-grade gliomas (Arm B). - People who...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06640582 · Essen Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 16 to 90 years old - People who have been diagnosed with brain glioma (a type of brain tumour) — including a first diagnosis, a return of the cancer, or cancer that has spread — confirmed through tissue testing - People whose doctors estimate they have a life exp...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06641908 · EMD Serono Research & Development Institute, Inc. Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 16 April 2027
🇧🇪 BE🇫🇷 FR🇯🇵 JP🇨🇭 CH🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - **Group A (Soft Tissue Sarcoma):** People who have been diagnosed with a type of cancer called soft tissue sarcoma (STS) that has spread or cannot be surgically removed, and whose cancer has gotten worse after at least one previous treatment that included a drug from the ant...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06649058 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People whose case has been reviewed by a specialist team that includes a cancer doctor, a radiation specialist who regularly performs a precise form of radiation called SRS, and a brain surgeon. - People whose specialist team estima...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06649851 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2027
🇺🇸 US

Who might be able to join this trial: - People who have been newly diagnosed with a specific type of brain tumour called glioblastoma multiforme (GBM), Grade 4, confirmed by tissue or molecular testing, with a gene pattern called "IDH wildtype." - People whose tumour testing shows a positive "MGMT promoter methylation...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06650163 · Jonsson Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a brain tumor, including brain metastases (cancer that has spread to the brain), any grade of glioma, or meningioma - People who are already scheduled to have standard surgical removal of their brain tumor as part...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06667726 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2028
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with a brain tumor - Your doctor has determined you need a special type of brain scan called an amino acid PET scan, for reasons such as planning surgery, planning radiation treatment, checking whether a tumor is growing...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06672575 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People whose ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scale called the Karnofsky Performance Status (confirm with trial site). - People who have been diagnosed with a specific type of br...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06679816 · Beijing Tiantan Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have a pituitary neuroendocrine tumor (a type of brain tumor near the pituitary gland) that can be treated with a specific type of keyhole surgery through the nose - Your tumor measures at least 2 centimeters at its widest point - Bef...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06687681 · Marzieh Ebrahimi Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 November 2025
Iran

**Who might be able to join this trial:** - People who have been newly diagnosed with a grade 3 or 4 brain tumour, falling into one of these specific types: Astrocytoma (IDH-mutant), Oligodendroglioma (IDH-mutant), Glioblastoma (IDH-wild type), Diffuse midline glioma, Diffuse hemispheric glioma, or Diffuse pediatric-ty...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06705036 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇨🇳 CN

Who might be able to join this trial: - You have a pituitary tumor that has grown into a nearby area of the skull called the cavernous sinus (an invasive tumor). - You have previously signed a consent form agreeing to share biological samples and health information for research purposes. - You are between 18 and 80 yea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06710249 · Peter Siesjö Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2026
🇸🇪 SE

Who might be able to join this trial: - People aged between 18 and 79 years old - People who have a known or suspected brain tumour (such as a tumour that has spread from elsewhere in the body, a meningioma, or a glioma) that is causing swelling in the brain and related symptoms - People who are alert and oriented, sco...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06718933 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are older than 18 years of age. - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system called ECOG PS (scores 0–2) (confirm with trial site). - People who are expec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06719440 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2031
🇧🇪 BE

Who might be able to join this trial: - People who are able to give their informed consent to participate - People who are 18 years of age or older - People whose general health and ability to carry out daily activities falls within a certain range, as assessed by a standard medical scale (WHO performance status 0–2 —...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06725953 · University of Oklahoma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who can speak and read English - People who are able to give their informed consent to participate - People who received treatment for a cancer that was not in the brain or spinal cord within the last three years, where that treatment include...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06728865 · Li-kun Chen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years who have a general health score (ECOG) of 0 to 2, meaning they are fully active to capable of limited self-care, and who are expected to live at least 3 months. - People whose lung cancer has been confirmed through tissue or cell testing to be a sp...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06740955 · The First Hospital of Jilin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been newly diagnosed with glioblastoma (a type of brain tumour), confirmed by laboratory testing of tumour tissue - People who have had surgery to remove all or part of the tumour, or to take a small sample (biopsy) - People aged 18 to 70 years old at the tim...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06752096 · Navigantis Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - People who are already scheduled to have a brain blood vessel procedure, such as a diagnostic brain artery scan, a procedure to block blood supply to a brain tumour called a meningioma, or a procedure to remove a blood clot causing a stroke — selected using the same standard...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06757153 · Zhongnan Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 August 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed through laboratory testing of tumour tissue - People whose glioblastoma has come back after previous treatment, where the returned tumour has been surgically removed and...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06773481 · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a consent form agreeing to take part in the study. - People who have been diagnosed with a specific aggressive brain tumour (CNS WHO grade 4 glioma), confirmed by a tissue biopsy, whose tumour has come back or grown after standard treatment as shown...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06776250 · University Health Network, Toronto Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 March 2028
🇨🇦 CA

Who might be able to join this trial: - People aged 18 or older who weigh more than 40 kg (approximately 88 pounds). - People who have given their informed consent before any study-related procedures begin. - People who have a specific type of brain tumour — a diffuse astrocytic or oligodendroglial tumour — confirmed b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06776458 · University of Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇦 CA

**Who might be able to join this trial:** **Case group (people with breast cancer):** - People who are biologically female - People who have gone through natural menopause (periods stopped on their own, not due to surgical removal of both ovaries) and have had no periods for at least 1 year - People who have used horm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06779890 · Georgia Tsaousi Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2026
🇬🇷 GR

Who might be able to join this trial: - You have been assessed by a doctor as being in generally good to moderate health before surgery (this is called ASA physical status 1–3) - You are scheduled for a planned or soon-to-be-needed surgery to open the skull and remove a brain tumor - You have read and signed a form agr...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06782984 · Chungnam National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with glioblastoma (a type of brain tumour), either for the first time or as a recurrence - People who have already received standard treatment, which includes surgery and a combination of chemotherapy (using a drug called temozolomide) and radiation...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06789666 · UNC Lineberger Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 25 years old at the time of joining the study. - People who had cancer before the age of 18 and have finished cancer treatment. - People who are willing and able to follow the study procedures, as determined by the study team. - People who have signed forms givi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06796543 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

Who might be able to join this trial: **Group A (newly diagnosed sarcoma):** - People who are under 39 years old at the time of joining the trial - People who are reasonably physically well and able to carry out daily activities (as measured by standard medical scoring tools) - People who have been newly diagnosed wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06797661 · Erasme University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇧🇪 BE

Who might be able to join this trial: - People who have had a brain scan showing a growth in the brain that may be able to be removed by surgery, and who have not yet had surgery, chemotherapy, or radiation treatment for it Who may not be able to join: - People who have previously had brain surgery - People who have b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06805305 · Diakonos Oncology Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2030
🇺🇸 US

Who might be able to join this trial: - People aged 18 years or older. - People with a suspected diagnosis of a specific type of brain tumour called glioblastoma IDH-wt (a classification based on 2021 world health organisation brain tumour guidelines) where surgery to remove most or all of the tumour is considered poss...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06807619 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have one or more brain tumors and are already planned to have brain surgery to remove or take a sample of the tumor. - People who also have cancer that has spread to the lining of the brain or spinal cord, as long as they also have a brain tumor t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06810336 · University of Virginia Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 10 September 2027
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 65 years old - You are scheduled to have brain surgery on the upper part of the brain (called supratentorial surgery) - Your overall health has been rated as acceptable for surgery by your anesthesia team (ASA status I, II, or III — confirm with trial site...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06810804 · Nantong Bencao Quadriga Medical Technology Co. Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with breast cancer (confirmed by biopsy from the original tumour site or a metastatic site) that has spread to the membranes surrounding the brain and spinal cord (leptomeningeal metastasis), confirmed by MRI scan or cerebrospinal fluid testing...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06815432 · Baylor College of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 5 December 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older with a brain tumour called glioblastoma that has come back after previous surgery, and who are planned for another surgery to remove tumour tissue - People whose tumour tests positive for a protein called GPC3, with a significant amount of the tumour...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06816927 · Duke University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have either a newly suspected diagnosis of GBM (a type of brain tumour) based on an MRI scan, or a confirmed GBM diagnosis who have not yet received radiation therapy or drug treatment for their brain tumour - People whose neurosurgeon be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06818331 · The Third Affiliated hospital of Zhejiang Chinese Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with a high-grade brain tumour called WHO Grade IV glioma, as defined by a specific Chinese cancer treatment guideline. - People whose tumour has come back (recurred) after surgery, confirmed by a brain MRI scan. - People who have at least one tumour that ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06822543 · Latin American Cooperative Oncology Group Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇧🇷 BR

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body, confirmed by a tissue test, where a specific marker called PD-L1 is present in fewer than 50% of tumour cells. - People whose tumo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06831461 · Tata Memorial Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2032
🇮🇳 IN

**Who might be able to join this trial:** - People who have a primary brain tumor (a tumor that started in the brain, not one that spread from elsewhere in the body) - People who are between 18 and 70 years old at the time of their radiation treatment - People who have a reasonably good level of daily functioning, as a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06831526 · Washington University School of Medicine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 28 February 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by laboratory testing to have a specific type of aggressive brain tumour called IDH-wildtype glioblastoma (grade 4), including a subtype called gliosarcoma, diagnosed according to 2021 medical guidelines. - People whose scans show that some tum...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06832384 · IRCCS Eugenio Medea Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 January 2026
🇮🇹 IT

**Who might be able to join this trial:** - People aged 0 to 25 years who have had surgery to remove a tumour located in the lower back part of the brain (called the posterior fossa) **Who may not be able to join:** - People who are currently taking part in a rehabilitation program that uses technological devices (suc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06835803 · Brigham and Women's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2028
🇺🇸 US

**Who might be able to join this trial:** - A tissue sample (biopsy) has confirmed a diagnosis of the most aggressive type of brain tumour, called glioblastoma (WHO grade 4, IDH wild-type), and this has been verified by a central review team. - The diagnosis is newly confirmed, and no more than 8 weeks have passed sin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06839560 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older on the day they sign the consent form. - People diagnosed with metastatic breast cancer that has spread to the brain, where the cancer tests negative for the HER2 protein, confirmed by accepted clinical standards. - People who have received no more th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06844838 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 or older who have a brain or nervous system condition requiring surgery (either in the upper or lower parts of the brain area) Who may not be able to join: - People with a history of psychiatric (mental health) illness or who are currently taking medications that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06850766 · Ottawa Hospital Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇨🇦 CA

Who might be able to join this trial: - People who are 18 years of age or older - People who have been newly diagnosed with a specific type of brain tumour called IDH-wildtype glioblastoma - People who have completed surgery to remove as much of the brain tumour as was safely possible - People who have completed radiat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06860594 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed (confirmed by lab testing of tissue or cells) with a recurring brain tumour called an astrocytic tumour — including GBM (grades 2–4, IDH-wildtype), Astrocytoma (grades 2–4, IDH-mutant), or Diffuse midline glioma (including certain tumour types with...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06867991 · The First People's Hospital of Changzhou Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 8 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 12 years or older - People who have been diagnosed with autoimmune encephalitis where the immune system is attacking proteins on the surface of nerve cells - People who have already tried at least one standard first-line treatment, such as: at least 3 days of hig...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06874426 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇧🇪 BE🇩🇪 DE🇳🇱 NL

Who might be able to join this trial: - You are an adult who is scheduled to have a type of surgery performed through the nose to treat a condition at the base of the skull (confirm with trial site) Who may not be able to join: - You already have no sense of smell before the surgery - You have previously had surgery t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06888817 · The Netherlands Cancer Institute Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2028
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 or older - People who have had their first episode of serious radiation-related brain injury (called symptomatic cerebral radiation necrosis, or sCRN) at least 3 months after completing a focused course of radiation treatment to the brain, where a specialist b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06894238 · Beijing Sanbo Brain Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older - People who are scheduled for a planned, non-emergency brain or nervous system surgery - People who are considered generally healthy or have only mild health conditions (as assessed by their medical team using a standard health classif...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06894979 · Children's Oncology Group Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 March 2028
🇺🇸 US

**Who might be able to join this trial:** - Children and teenagers aged 12 months to under 18 years old (for the dose escalation phase), or aged 12 months to under 22 years old (for the disease expansion phase) at the time of joining the study. - People with a newly diagnosed high-grade brain tumour, diffuse midline g...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06896331 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇮🇹 IT

Who might be able to join this trial: - People who have a primary or secondary tumor in the brain or cerebellum, where the surgical plan involves removing at least part of the tumor. Who may not be able to join: - People who have a primary or secondary tumor in the brain or cerebellum, where the surgical plan involves...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06899516 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with a brain tumor. - People who own at least one pet. Who may not be able to join: - People who do not wish to take part in the study. - People who are unable to complete the questionnaire. Important: Always verify eligibility with the trial site...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06910306 · Alpha Tau Medical LTD. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 85 years old - People who have been diagnosed with a grade IV brain tumour called glioblastoma (including types such as gliosarcoma or giant cell glioblastoma), confirmed by laboratory testing of tumour tissue - People whose tumour has come back in a single...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06914479 · University of Michigan Rogel Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2031
🇺🇸 US

**Who might be able to join this trial:** - You are between 3 and 25 years old and have been diagnosed with a cancerous brain tumor that has come back, gotten worse, or stopped responding to treatment, and you have already completed standard first-line treatment - You are between 26 and 39 years old and have been diag...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06922487 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇸🇪 SE

Who might be able to join this trial: - People who are over 18 years old - People who are having planned (non-emergency) surgery to remove a brain tumor, either in the upper or lower part of the brain, through an opening in the skull - People whose surgery requires them to be awake during the procedure - People whose t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06922500 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇸🇪 SE

Who might be able to join this trial: - Adults who are scheduled to have a planned (non-emergency) brain surgery to remove a tumor - People who are able to give their informed consent to take part in the trial Who may not be able to join: - People whose brain tumor affects their thinking or understanding in a way that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06928298 · University of Texas at Austin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are 60 years of age or older - People from any ethnic or racial background, in line with NIH diversity guidelines - People of any gender (male or female) - People who are fluent in Spanish Who may not be able to join: - People who have a health condition that could ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06930846 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** **For people with brain cancer:** - Adults aged 18 or older - Service members, Veterans, or civilians who have been diagnosed with brain cancer (not including glioblastoma) - People diagnosed with a primary brain tumor — such as low-grade glioma, oligodendroglioma, IDH mutant...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06933199 · University Hospital Ostrava Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇿 CZ

**Who might be able to join this trial:** - People who are 18 years of age or older - People whose general health and ability to carry out daily activities meets a minimum functional threshold (known as a Karnofsky Performance Status score of 60 or above — confirm with trial site if unsure what this means for a specifi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06934889 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form. - People who have been diagnosed with Grade IV Glioblastoma or Gliosarcoma (a specific type of aggressive brain tumour), as classified under the 2021 WHO system, including a molecular GBM diagno...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06936046 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily, have been fully informed about the study, and are able to sign a consent form and follow all study procedures. - People aged 18 or older (any gender). - People who have been formally diagnosed with glioblastoma (GBM) through a tiss...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06938555 · Arizona State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with breast cancer, at any stage - People who finished a course of chemotherapy (before or after surgery) at least 3 months ago — those currently on maintenance or palliative systemic therapy may also be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06943742 · Guangzhou Women and Children's Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - Children and teenagers between 3 and 18 years old - People who have been diagnosed with a brain tumor - People who are able to cooperate with a type of brain activity scan called magnetoencephalography (a non-invasive test that measures electrical activity in the brain) Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06949891 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇳🇱 NL

Who might be able to join this trial: - People who are male or female and aged 18 or older - People who have been diagnosed with acromegaly (a condition caused by a pituitary tumour that leads to too much growth hormone), confirmed by elevated growth hormone and/or IGF-I levels in the blood - People whose IGF-I levels...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06954636 · Sied Kebir Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇩🇪 DE

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been newly diagnosed with a specific type of brain tumour called glioblastoma (IDH wild-type) - People who have never previously received chemotherapy - People who have never previously received radiation treatment to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06962215 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older - People who are covered by a social security (health insurance) scheme - People who have signed a form agreeing to take part in the trial - People who have been found to have a brain tumor that may be cancerous, whether it started in the brain or spread f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06964815 · Istituto Oncologico Veneto IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇮🇹 IT

Who might be able to join this trial: - People who have recently been diagnosed with glioblastoma (a type of brain cancer), confirmed by a tissue sample, following the 2021 WHO diagnostic guidelines - People whose tumor tissue has been tested for a specific protein marker called MGMT methylation status, with results a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06967285 · Sichuan Provincial People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with Acute Respiratory Distress Syndrome (ARDS), a serious lung condition, where oxygen levels in the blood are severely low (PaO₂/FiO₂ below 150 mmHg), and who require treatment where they are turned face-d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06973096 · University of Pennsylvania Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2042
🇺🇸 US

**Who might be able to join this trial:** **Before radiation treatment starts (Step 1):** - Adults aged 18 or older who have agreed to take part by signing a consent form - People who have been newly diagnosed with a specific type of brain tumour called glioblastoma, confirmed by laboratory testing to have certain gen...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06973824 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 February 2028
🇮🇹 IT

Who might be able to join this trial: - People who have had surgery for a pituitary tumour - People who have had their pituitary tumour confirmed by a pathology (tissue) test - People who were older than 18 years of age at the time of their pituitary tumour diagnosis - People who have had at least 2 years of follow-up...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06974370 · University of Vermont Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a solid tumour cancer, confirmed by laboratory testing of tissue or cells within the past 5 years (or with more recent imaging or tissue confirmation if the original diagnosis was longer ago) - People who are starting, or planning to start...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06975332 · Medical University of Warsaw Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇵🇱 PL

**Who might be able to join this trial:** - People aged 18 to 80 years old - People who have been diagnosed with a specific type of brain tumour called diffuse glioma (a higher-grade type, classified as WHO Grade 3 or 4), confirmed by laboratory testing of tumour tissue - People who have already completed standard tre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06981156 · University of Wisconsin, Madison Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - The person with the brain or spine tumour must be at least 1 year old - The person must be seen in a paediatric (children's) clinic - The brain or spine tumour must have been confirmed at the time of first diagnosis, either through imaging (such as an MRI or CT scan) or through a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06989086 · Virginia Commonwealth University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** **For patients:** - You have been told by a doctor that you have a primary malignant brain tumor (a brain tumor that started in the brain, rated on a scale of grades 2 to 4) - It has been more than 2 weeks since you had brain surgery or a biopsy - You have reported a higher le...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06991101 · Baptist Health South Florida Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older of any sex, gender, race, or ethnicity. - People who have signed a consent form and are willing to follow all study procedures for the full duration of the trial. - People who have been diagnosed with a specific type of brain tumour called glioblastoma (ID...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06992973 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 September 2029
🇮🇹 IT

**Who might be able to join this trial:** - People who have a single brain metastasis (cancer that has spread to the brain) that is 3 cm or larger in size, or a single brain metastasis between 2 cm and 3 cm that is causing symptoms and can be removed with surgery — with or without up to 3 additional small brain lesion...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06995313 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 July 2026
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with hemianopia (a condition where vision is lost in half of the visual field in one or both eyes), confirmed through specific vision testing including microperimetry - People whose vision loss has been present for more than 6 months - People betwee...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07003139 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇹🇼 TW

Who might be able to join this trial: - Adults aged 18 years or older. - People who have a malignant (cancerous) brain tumour confirmed by tissue testing and/or brain scans, classified as a high-grade tumour (WHO Grade 3 or 4), but not certain specific tumour types (Grade 3 ependymoma, medulloblastoma, or primary CNS l...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07003542 · Case Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of aggressive brain tumour (WHO grade 4 glioma) confirmed by laboratory testing, and for whom surgery to remove the tumour is already planned. - People who have never previously taken sitagliptin (also known as a "gliptin") as a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07006155 · Valentina Garibotto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
🇨🇭 CH

Who might be able to join this trial: - You have given written consent to take part in the study. - You are between 18 and 85 years old. - You are willing and able to follow all the study requirements, as decided by the study doctor. Who may not be able to join: - You are currently pregnant. - You are unable to lie st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07008287 · Innovent Biologics (Suzhou) Co. Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the body (Stage IV), confirmed by a lab test on a tissue or cell sample - You have at least one tumor that can be mea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07017816 · Children's National Research Institute Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have a brain or central nervous system (CNS) cancer that has come back, kept growing, or stopped responding to treatment, and for which no known cure exists — including certain tumour types such as medulloblastoma, high-grade gliomas, ependymomas, and similar seri...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07021339 · University Hospital, Bonn Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 February 2028
🇩🇪 DE

**Who might be able to join this trial:** - Your brain scan (MRI) shows a suspected type of brain tumor called glioblastoma that lights up with contrast dye - A tissue sample taken during surgery confirms a newly diagnosed aggressive (high-grade) brain tumor - Your tumor is located in the temporal lobe (a specific reg...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07044557 · University of Louisville Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You have one or more new brain tumors that have shown up on a brain scan - You have a mass (lump or growth) in your body that is suspected or confirmed to be a tumor - If you have a lung mass that may be lung cancer and have not yet been diagnosed, you must have a biopsy of t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07045935 · University Hospital, Basel, Switzerland Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2029
🇨🇭 CH

**Who might be able to join this trial:** - You are an adult aged 18 or older who has been diagnosed with a prolactinoma (a type of benign tumour on the pituitary gland) that is causing high prolactin hormone levels in your blood - Your prolactin levels are at least twice the upper limit of what your local lab consider...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07049094 · Zhejiang University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 25 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People classified as having a low-to-moderate anaesthetic risk (a rating system doctors use called ASA Class I, II, or III) - People who are booked for a planned (non-emergency) brain surgery - People who have given their own written consent, or whos...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07053033 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form. - People who are willing to follow all study procedures and are available for the full duration of the study. - People who are 18 years of age or older. - People whose general health...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07076498 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - You (or your child) must be at least 36 months (3 years) old - You have been newly diagnosed with a specific type of brain tumor called diffuse midline glioma (DMG) with a particular genetic change (H3 K27M), or a brain stem tumor called DIPG that has been confirmed by imagi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07087002 · Stanford University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with medulloblastoma or another type of primary brain embryonal tumour (such as ETMR, Pineoblastoma, ATRT, CNS neuroblastoma FOXR2-activated, or CNS Embryonal Tumour NOS), confirmed by laboratory testing of tumour tissue according to the 2021 W...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07089641 · Jonsson Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form - People who have been diagnosed through a tissue biopsy with a specific aggressive brain tumour (WHO Grade IV glioblastoma or astrocytoma) that has come back or continued to grow after radiation treatment, with...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07093814 · Guangzhou Virotech Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part, have been fully informed about the study, and are happy to follow all the trial steps - You are between 18 and 70 years old (inclusive) at the time of signing the consent form - You have been diagnosed with glioblastoma (a type of brain tumour) t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07100600 · Henan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 July 2030
🇨🇳 CN

**Who might be able to join this trial:** - Women aged 18 or older - People who have been diagnosed through laboratory testing with HER2-positive advanced breast cancer - People who have at least one measurable tumour in the brain (according to specific measurement guidelines called RANO-BM criteria) that has not yet...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07111182 · University of Illinois at Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 years or older who are admitted to a neurosurgery department for surgery to remove a suspected high-grade brain tumour (grade 3 or 4 glioma) using a special dye called 5-ALA during the operation - People aged 18 years or older who are admitted to a neurosurgery dep...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07117864 · QIAO LI Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are a woman aged 18 to 75 years with breast cancer that has been confirmed by a tissue sample (biopsy). - Your general health and ability to carry out daily activities falls within an acceptable range (a score of 0 to 2 on a standard medical scale — confirm with trial si...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07119294 · Jules Bordet Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇧🇪 BE

**Who might be able to join this trial:** - People aged 18 years or older - People who have a brain lesion that brain scans suggest may be glioblastoma (a type of brain tumour), or whose glioblastoma may have come back - People whose general health and ability to carry out daily activities falls within an acceptable ra...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07121842 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with glioblastoma (a type of brain tumor), confirmed through laboratory analysis of a tissue sample taken during surgery, or it is suspected based on brain scans - You are planned to receive radiation therapy, either on its own or combined with chemoth...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07126821 · Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a brain tumor, confirmed through a tissue or lab test (pathology) - You have been diagnosed with another type of brain condition through appropriate medical testing - Your full medical records and case information are available and complete - *(F...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07129317 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2035
🇺🇸 US

Who might be able to join this trial: - People receiving either proton or photon radiation therapy as part of their treatment. Who may not be able to join: - People who are older than 26 years of age. Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07132190 · Ayal A. Aizer, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a solid cancer (confirmed by biopsy) that has spread to the brain, with at least one brain tumor that shows up on a scan or has been confirmed by biopsy, AND that tumor meets at least one of these conditions: - It has been growing by at least 1...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07134153 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have HER2-expressing breast cancer that is advanced or has spread to other parts of the body - People whose cancer has spread to the membranes surrounding the brain and spinal cord (leptomeningeal metastasis) - People with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07134842 · University College, London Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
🇬🇧 GB

**Who might be able to join this trial:** - People who have been newly diagnosed with a specific type of brain tumour called glioblastoma (or gliosarcoma) located in the upper part of the brain, confirmed by imaging or tissue testing - People aged 18 or older - People who are generally well enough to carry out normal...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07136428 · Duke University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2030
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of giving consent - People with HER2-positive metastatic breast cancer that has spread to the brain, with at least one brain tumour larger than 5mm that is new or growing (previous local treatment to other brain lesions is allowed) - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07139990 · University of Texas Southwestern Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** This trial has two separate groups (Cohort A and Cohort B). A person would need to meet the criteria for one of these groups. **Cohort A:** - Adults aged 18 or older - Have a general health and activity level that falls within a certain range, as assessed by a doctor using a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07140601 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 years or older. - People who are able to understand and agree to take part in the research. Who may not be able to join: - People who do not wish to participate. - Women who are currently pregnant or breastfeeding. Important: Always verify eligibility with the tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07141732 · Joint Stock Company European Medical Centre Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2026
🇷🇺 RU

**Who might be able to join this trial:** - You must be between 40 and 75 years old. - You must be in reasonably good general health and able to carry out most daily activities (confirm with trial site regarding the specific fitness score used). - You must be able to understand and sign a consent form on your own, wit...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07144735 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old (inclusive), of any sex - People who have at least one tumour area that can be assessed, with a confirmed diagnosis of glioblastoma (a type of brain tumour classified as WHO Grade IV), and scan results suggesting the tumour has continued to gro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07145047 · Mianyang Central Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with glioblastoma (a type of brain tumour) that has come back, where the medical team has determined that standard treatments are no longer working - People whose returning glioblastoma has been confirmed through a laboratory examination of tumour tissue - P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07145112 · University of California, Davis Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by a pathology report using the 2021 World Health Organization classification. - People whose brain scans show that the tumour has grown or returned after previous treatment. - People who ha...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07162246 · Sunnybrook Health Sciences Centre Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2029
🇨🇦 CA

**Who might be able to join this trial:** - People who have up to two large tumours that have spread to the brain - People who have up to 10 brain metastases (tumours that have spread to the brain) in total at the time of enrolment — these may be previously untreated or may have grown back after earlier treatment - Pe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07174661 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People who were between 18 and 39 years old when they were first diagnosed with cancer - People diagnosed with a stage III or IV solid tumour (a cancer that forms a solid mass), or a high-grade brain tumour, within the last 12 months — this also includes people whose cancer was p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07179926 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with acromegaly (a condition where the body produces too much growth hormone) that was not brought under control after 6 months of treatment with a type of medication called first-generation somatostatin receptor lig...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07180927 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form - People aged 2 to 70 years old - People who have a brain tumor that has come back or has not responded to treatment, with tumors that can be measured on scans, and who have already re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07186556 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are currently between 18 and 39 years old - People whose primary brain tumor was first diagnosed when they were between 15 and 39 years old - People who finished curative treatment between 6 months and less than 5 years ago - People who were treated with both chem...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07193628 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to follow the trial treatment plan and visit schedule, and who agree to sign a written consent form. - People aged between 18 and 75 years old (inclusive) on the day they sign the consent form, of any gender. - People whose general physical functioning is r...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07193654 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 of any gender - People who have been recently diagnosed with a high-grade (grade 4) brain tumour, with at least one measurable tumour area, and where scans suggest the tumour has spread toward the fluid-filled spaces or outer coverings of the brain - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07195591 · GT Medical Technologies, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2031
🇺🇸 US

"Who might be able to join this trial: - People who are 18 years of age or older. - People whose brain scans suggest they may have a newly diagnosed type of brain tumour called glioblastoma (GBM). (Note: if laboratory results later show a specific genetic change called an IDH mutation, those people will still be monito...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07197632 · Technical University of Munich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇩🇪 DE

"Who might be able to join this trial: - People who have been recommended by their doctor to have surgery to remove cancer that has spread to the brain Who may not be able to join: - People who are under 18 years of age - People who have a medical reason that prevents them from having a high-strength (3 Tesla) MRI sca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07198256 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with a brain tumour (specifically glioma, brain metastases, or brain lymphoma) confirmed by a tissue sample (biopsy or surgery). - You are at least 18 years old. - You had a complete MRI scan of your brain before any surgery. Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07209241 · University of Pennsylvania Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2042
🇺🇸 US

**Who might be able to join this trial:** - People who have signed a written consent form agreeing to take part in the study - Adults aged 18 or older - People who have been diagnosed with a specific type of brain tumour called glioblastoma (IDH-wildtype, as classified by WHO 2021 guidelines) that has come back after...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07215910 · Alliance for Clinical Trials in Oncology Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 May 2033
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of brain tumour called an IDH-mutant astrocytoma, grade 3 (a moderately aggressive brain tumour with a particular genetic change), confirmed by a central review team. - People whose tumour tissue slides and samples are available...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07216157 · Maria Sklodowska-Curie National Research Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇵🇱 PL

Who might be able to join this trial: - People who are 18 years of age or older - People who are already scheduled to have a type of nasal/sinus surgery (endoscopic endonasal surgery) that involves a standard repair of the base of the skull - People who have given written consent to participate before the study begins...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07223034 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed brain tumour diagnosis of a specific type of glioma (grade 2–4), identified by laboratory testing as IDH1 R132H-wildtype, including types such as glioblastoma, diffuse astrocytoma, diffuse midline glioma, or related types - People whose tumour tis...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07224451 · Sheba Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇮🇱 IL

Who might be able to join this trial: - People who are 18 years of age or older - People who are able to read, understand, and sign a consent form agreeing to take part - People who are scheduled to have surgery to remove a tumor inside the spinal canal, where nerve monitoring is used during the operation Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07224503 · Virginia Commonwealth University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇺🇸 US

Who might be able to join this trial: **Patients:** - People who receive care at the Virginia Commonwealth University Neuro-Oncology clinic - People who have a confirmed primary brain tumor diagnosis, either through a tissue sample (biopsy) or a specialist's review of brain scans - People who show reduced ability in a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07225621 · Alpheus Medical, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have given written consent showing they understand the study and agree to follow its requirements - People aged between 18 and 80 years old - People who are reasonably functional in daily life, as measured by a standard medical scale (WHO performance status of 2 o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07227610 · Medical University of South Carolina Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 February 2029
🇺🇸 US

Who might be able to join this trial: - The patient, or a legally authorised representative on their behalf, must be willing and able to give consent to take part in the study before it begins. - The person must be willing to follow all study procedures and be available for the full length of the study. - Adults aged 1...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07236840 · Tata Memorial Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇮🇳 IN

**Who might be able to join this trial:** - You or your child has been diagnosed with a brain tumor (confirmed by scan or tissue sample) - The patient is older than 5 years of age - You or your caregiver has access to an Android smartphone and is able to download and use a mobile app - Doctors expect the patient to liv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07243470 · Centre Leon Berard Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2029
🇫🇷 FR

**Who might be able to join this trial:** - People aged 12 years or older at the time of signing the consent form. - People who have been confirmed by a tissue test (biopsy or surgery sample) to have a malignant (cancerous) brain or central nervous system (CNS) tumour of specific types, including high-grade glioma wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07248228 · Case Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a solid tumour (confirmed by tissue sample, cell sample, or imaging) that has spread to the brain - People who are older than 18 years of age - People who are well enough to carry out most daily activities, as measured by a standard medical sca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07251868 · Peking University Cancer Hospital & Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are at least 18 years old, and there is no restriction on gender - You are able to understand what the study involves and are willing to sign a consent form — or, if you have difficulty understanding or communicating, a legal guardian can sign on your behalf - Your full...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07263438 · Centre Hospitalier Universitaire Vaudois Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 March 2028
🇨🇭 CH

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by laboratory analysis of tumour tissue or cells, according to 2021 World Health Organization classification, whose tumour has clearly come back for the first time after completing standard...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07268053 · Nader Sanai Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with glioblastoma (GBM) according to 2021 WHO criteria whose cancer has continued to grow or returned after standard treatment, including surgery (or biopsy if full surgery was not safe) and combined chemotherapy and radiation therapy. - People diagnosed wit...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07268183 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 January 2027
🇫🇷 FR

**Who might be able to join this trial:** *For the main study group (cases):* - Female patients who are 18 years of age or older at the time of joining the study (the original diagnosis may have happened before age 18) - People with a diagnosis of a larger prolactin-producing pituitary tumour (called a macroadenoma) m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07274397 · Beta Emitting Accurate Monitored Systems Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 April 2027
🇫🇷 FR

Who might be able to join this trial: - People who have had their first surgery to remove a suspected glioblastoma (a type of brain tumour) within the past 72 hours - People who have given their signed agreement to take part in the trial Who may not be able to join: - People who are in legal custody or under a form of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07282470 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed for the first time with a single meningioma (a type of brain tumour) located on the outer surface of the brain (called the convexity) - People who have had surgery where the surgeon was able to remove the entire...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07284069 · Aarhus University Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 November 2028
🇩🇰 DK

**Who might be able to join this trial:** - People aged 18 years or older - People whose brain scans and specialist team assessment suggest a diagnosis of GBM (a type of brain tumour), based on a full brain MRI scan taken within the past 4 weeks - People whose medical team has determined that surgery is appropriate, fo...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07284628 · University of Zurich Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2029
🇨🇭 CH

Who might be able to join this trial: - Adults aged 18 or older - People who have been newly diagnosed with glioblastoma (a type of brain tumour), confirmed through laboratory analysis of tumour tissue, classified according to the 2021 WHO brain tumour guidelines - People whose tumour has been tested for a specific gen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07301268 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been confirmed by tissue testing to have a brain tumour classified as one of the following: a progressive or returning WHO grade IV glioblastoma (IDH wildtype, including molecular glioblastoma and gliosarcoma), or a WHO grade 4 astro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07304739 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old, of any gender - People whose lung cancer has been confirmed by tissue testing to be a type called lung adenocarcinoma, which cannot be removed by surgery or cured with radiation, and has either spread locally or to other parts of the body...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07316101 · West China Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years of age - People who have had a brain scan (MRI or CT) showing a pituitary adenoma or craniopharyngioma (types of brain tumour near the base of the skull) that is 3 cm or smaller and has not spread widely into the surrounding skull area - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07318818 · Tasly Pharmaceutical Group Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 February 2028
🇨🇳 CN

Who might be able to join this trial: - People who have given voluntary written consent to participate - Adults aged 18 to 70 years (inclusive), of any sex - People with glioblastoma (a type of brain tumour, grade 4, IDH wild-type) that has come back or continued to grow, confirmed through tissue or molecular testing a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07321353 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a brain tumor that developed in childhood - People whose tumor treatment (which must have included surgery, radiation, or chemotherapy) was completed more than 12 months ago - People who live with a parent or guardian - People whose primary spo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07323966 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇧🇪 BE

Who might be able to join this trial: - You are 18 years old or older - You have a brain tumor that has been treated with a type of radiation therapy given in multiple sessions over time - You are able to read and fill out a questionnaire written in French Who may not be able to join: - You are unable to stay still (f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07326566 · Black Diamond Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with a type of brain cancer called glioblastoma (GBM), confirmed through a tissue sample, with a specific biological marker called IDH wild type. - People whose brain tumor tests positive for a protein called EGFR, based on a certified la...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07332377 · Virginia Commonwealth University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You have finished cancer treatment and your doctors have found no signs of the cancer remaining (complete remission). - You were diagnosed with cancer within the last three years. - You are currently experiencing pain related to your cancer or the treatment you received. - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07335315 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** *For the Contrast-Based part of the trial:* - You have been diagnosed with Cushing's disease, or you need surgery to remove a certain type of brain tumor near the pituitary gland (a non-corticotroph adenoma) - You have agreed to have a specific type of surgery to remove the tu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07338526 · Tata Memorial Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 July 2035
🇮🇳 IN

Who might be able to join this trial: - Children and young people who were between 6 and 16 years old at the time of radiation treatment - People whose general health and ability to carry out daily activities meets a minimum functional level, as measured by standard medical scoring tools (confirm with trial site) - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07341464 · Société des Produits Nestlé (SPN) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 November 2026
🇬🇧 GB

Who might be able to join this trial: - Children between 1 and 15 years old, or adults aged 15 and above, who need one or more extra "bolus" (larger, less frequent) tube feeds on top of their usual tube feeding or home-blended food diet to help manage malnutrition related to a medical condition. - Patients who are alre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07343986 · University of Virginia Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with a specific type of brain tumour (supratentorial glioblastoma or gliosarcoma) that has certain molecular characteristics (IDH wildtype, MGMT unmethylated) and expresses a protein called EGFR, confirmed by pathology review at UVA. - Pe...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07346144 · Trogenix ltd Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2030
🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 70 years old - People whose general health and ability to carry out daily activities meets a minimum level of functioning (confirm with trial site) - People newly diagnosed with a high-grade brain tumour in one specific area on one side of the brai...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07355348 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇨🇦 CA

Who might be able to join this trial: **Patients:** - People who have been diagnosed with cancer that has spread to the brain (from any type of primary cancer) - People who are currently receiving follow-up care at a Brain Metastases Clinic - People aged 18 or older - People who are able to speak, read, and write in E...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07361562 · Cogent Biosciences, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of an advanced, spreading, or inoperable solid tumour with specific genetic changes (called ERBB2-activating alterations, NRG1 gene fusions, or HER2 overexpression) detected in a blood or tumour test — this applies to Part A of the trial...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07381959 · Uppsala University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2031
🇸🇪 SE

**Who might be able to join this trial:** **Group A – Children treated with radiation:** - Children and teenagers aged 0–17 years old - Children who have been diagnosed with a primary brain tumour through surgery, biopsy, or another diagnostic method, at Uppsala University Hospital or another university hospital in Sw...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07383649 · The Methodist Hospital Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are male or female and older than 18 years of age at the time of signing consent - People who have breast cancer that has spread to the brain (in the upper and/or lower parts of the brain) and is continuing to grow, with at least one affected area that has not yet...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07387666 · University of Texas Southwestern Medical Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with glioblastoma (a type of brain tumor). - You have been newly diagnosed and have not yet had any surgery, radiation, chemotherapy, or other treatment for this tumor. - You are 18 years of age or older. - You are able to carry out most daily activities a...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07391215 · Institute of Cancer Research, United Kingdom Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 19 January 2029
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of brain tumour called glioblastoma (IDH-wildtype Grade 4), confirmed through laboratory testing of tumour tissue. - People who have had their tumour's genetic information (whole genome and transcriptome data) analysed thro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07392957 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of aggressive brain tumour (WHO grade 4, IDH wild-type glioma) that has come back after standard treatments such as radiation, chemotherapy, and/or tumour-treating fields, with no more than two recurrences confirmed. - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07396454 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - Women between 18 and 70 years old (age calculated on the day consent is signed) - People whose general health and ability to carry out daily activities meets a minimum score on a standard medical scale, or who score slightly below that threshold only because of neurological...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07396896 · Meyer Children's Hospital IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with a tumour affecting the hypothalamus or the area around the optic chiasm (a specific part of the brain), as classified by the WHO 2021 guidelines. - People who have developed obesity linked to hypothalamic damage — specifically, those over 5 yea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07411690 · Medical University of Warsaw Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇵🇱 PL

Who might be able to join this trial: - Adults aged 18 or older - People who have been assessed as needing a type of brain surgery called a craniotomy for a tumor located in the upper part of the brain Who may not be able to join: - People who would be having a repeat surgery because a brain tumor has come back - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07413796 · Medical University of Warsaw Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇵🇱 PL

Who might be able to join this trial: - People who are male or female and are at least 18 years old - People who have been assessed as needing a craniotomy (a type of brain surgery where part of the skull is temporarily removed) for a tumor located in the upper part of the brain Who may not be able to join: - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07415668 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2029
🇨🇭 CH

Who might be able to join this trial: - People who are willing and able to give informed consent to participate - People who are 18 years of age or older - People who have a brain metastasis (a cancer that has spread to the brain) that is located in or very close to the part of the brain that controls movement (the pri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07416188 · National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2030
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed by a specialist brain pathologist with glioblastoma (a type of brain tumour) that has come back after previous treatment, and whose tumour has a specific characteristic called IDH-wildtype - People whose general health...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07417072 · Meyer Children's Hospital IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇮🇹 IT

Who might be able to join this trial: - The patient is between 3 and 18 years old and has a suspected brain tumour for which they are having brain surgery - The patient has not previously had a bone marrow transplant or similar blood-related procedures that could affect genetic testing results - The patient has not rec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07417085 · Meyer Children's Hospital IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇮🇹 IT

Who might be able to join this trial: - People aged between 3 and 18 years old who are suspected of having a brain or spinal cord tumour and are scheduled to have brain or spinal surgery. - People who have not taken antibiotics or probiotics for a long period of time in the three months before samples are collected for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07418775 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2031
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You are able to speak and read English - You have been diagnosed with a meningioma (a type of brain tumour) Who may not be able to join: - You are currently experiencing serious mental health issues, such as thoughts of suicide, active psychosi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07424092 · Clinica Universidad de Navarra, Universidad de Navarra Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 May 2029
🇳🇱 NL🇪🇸 ES

Who might be able to join this trial: - The patient (or their parent or legal guardian, if applicable) must agree to participate in writing, and younger patients must also provide written agreement where required by their age and country. - People with a brain tumor diagnosis — specifically high-grade glioma, medullob...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07426848 · Royal College of Surgeons, Ireland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇮🇪 IE

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with a primary brain tumour (a tumour that started in the brain) - People who are currently receiving cancer treatment delivered through the body, such as chemotherapy or targeted therapy - People who are ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07428616 · Exelixis Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 February 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a meningioma (a type of brain tumour) confirmed by tissue testing, specifically World Health Organization (WHO) grade 1, 2, or 3. - People whose tumour has come back or continued to grow after standard treatments such as surgery and/or radiatio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07441707 · Ipsen Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 July 2030
🇯🇵 JP

**Who might be able to join this trial:** - People aged 6 months to 25 years (inclusive) who have at least two generations of Japanese ancestry, at the time of signing the consent form. - People who have a low-grade brain tumour (glioma) that has come back or continued to grow, and whose tumour has been confirmed by l...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07456878 · Mayo Clinic Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 75 who have been diagnosed with Cushing's disease, Acromegaly, or a tumour-related high prolactin level, confirmed through blood or urine tests according to current specialist guidelines. - People whose recent specialised MRI scan (called a DCE-MRI) did not clea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07459101 · Sunnybrook Health Sciences Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2029
🇨🇦 CA

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma or a grade 4 astrocytoma (a type of brain tumour), confirmed through a biopsy or surgical removal of tumour tissue - People whose doctors have determined that combined chemotherapy and radiation treatment (using a drug called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07460232 · Mayo Clinic Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 April 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific hormone condition called Cushing disease, confirmed through blood or urine tests showing overproduction of a hormone called ACTH. - People who have not had previous surgery on the pituitary gland (a small gland at the base of the bra...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07461948 · Jonsson Comprehensive Cancer Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 27 October 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People who have a confirmed or suspected diagnosis of glioblastoma (a type of brain tumour) - People who are already scheduled to have standard surgery to remove a brain tumour or take a small tissue sample (biopsy) - People whose most rec...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07462507 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2031
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older, of any race or gender - You are able to sign a consent form yourself, or you have a legally authorized person (such as a family member or guardian) who can sign on your behalf - You have been diagnosed with a brain or spinal cord tumor (either on...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07464925 · Tetragon Biosciences Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of giving consent to participate - People who have been diagnosed with a Grade 3 or Grade 4 glioma (a type of brain tumour), confirmed by a tissue sample test - People whose brain tumour has come back or continued to grow after previous tr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07476781 · Sunnybrook Health Sciences Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with a solid tumour cancer that has spread to other parts of the body, and you fall into one of three groups: (A) cancer that has spread to the fluid around the brain and/or spinal cord (with or without tumours in the brain itself), (B) tumours in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07476794 · Sunnybrook Health Sciences Centre Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇨🇦 CA

**Who might be able to join this trial:** - People aged 65 years or older - People who have been diagnosed with a specific type of brain tumour called glioblastoma (WHO grade 4, IDH wild-type GBM), confirmed by laboratory testing of tumour tissue - People whose tumour has a specific genetic characteristic called an un...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07480941 · Beijing Biotech Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 18 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing the consent form - People who have been diagnosed with glioblastoma (a specific type of aggressive brain tumour, graded as WHO grade 4) or a related high-grade brain tumour (WHO grade 3 or 4) that has come back or continu...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07485452 · Maastricht University Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with non-small cell lung cancer (NSCLC) that has spread to other parts of the body, with a specific gene change called an EGFR mutation, and who are currently being treated with the medication osimertinib as part of their regular care, with scans sh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07488754 · Medical University of Warsaw Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇵🇱 PL

**Who might be able to join this trial:** - Adults between 18 and 80 years old - People who have been diagnosed with a type of brain tumour called diffuse glioma (a higher-grade type, classified as Grade 3 or Grade 4 by the World Health Organisation), confirmed by laboratory testing of tumour tissue - People who have a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07492316 · University of Florida Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged older than 3 years and up to and including 39 years old - People who have a brain tumour called medulloblastoma (MB) that has come back or is getting worse for the first or second time, either confirmed by tissue testing or strongly suspected - People who have pr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07501156 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form - People aged 2 to 70 years old - People diagnosed with a returning or treatment-resistant brain tumour called diffuse midline glioma or diffuse intrinsic pontine glioma, confirmed to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07501559 · Jecho Biopharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2030
🇨🇳 CN

Who might be able to join this trial: - People aged 18 years or older. - People who have been diagnosed with glioblastoma (a type of brain tumour) that has come back, confirmed by tissue testing or brain scan, with tumour lesions of a certain size (no larger than 3 cm on a contrast MRI scan taken before the study drug...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07505173 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent to take part before enrolling - People aged between 18 and 75 years - People who have been diagnosed with a specific type of lung cancer called non-small cell lung adenocarcinoma, confirmed by laboratory tissue testing, and whose tumour...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07506239 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - Children and young people aged 2 to 25 years who have a low-grade brain tumour (a slow-growing type of brain tumour called LGG) that has come back or kept growing after at least one previous treatment (which may have been surgery alone or other treatments). - The tumour must have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07512154 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2031
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with glioblastoma or grade 4 astrocytoma, confirmed by a tissue test (biopsy or surgery) - People aged 18 or older - People who are well enough to carry out some daily activities (measured by a standard health scale called the Karnofsky Performa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07530536 · Brian J.Gill Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People between 22 and 65 years old who have had surgery to remove a brain tumor - People who have received prior treatments of other kinds (previous TMS — transcranial magnetic stimulation — therapy is the one exception; prior TMS would not be accepted) - People who have ong...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07538128 · Huashan Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 27 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are over 18 years old (male or female) - Your doctors expect you to live for at least 12 weeks - You are able to carry out most daily activities and care for yourself (confirm with trial site regarding the specific activity score required) - You have been diagnosed with...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07541781 · Kailin Yang, MD, PhD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 11 June 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a confirmed grade 4 brain tumour (glioma) that has come back or gotten worse after the first round of treatment, as determined by their treating doctor - People who have never been treated with sitagliptin or bevacizumab for this brain tumour -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07544992 · City of Hope Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 4 November 2031
🇺🇸 US

Who might be able to join this trial: - Participants must have given documented informed consent, or have a legally authorised representative who has done so. - Stored tumour tissue from a previous biopsy must be available for use, though exceptions may be considered with approval from the lead study doctor (confirm wi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07547163 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇮🇹 IT

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed with a specific type of slow-growing brain tumour called an IDH mutant grade 2 glioma, confirmed by a tissue sample (biopsy) - You agree to receive the treatment involved in the trial - You agree to fill in regular questionn...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07551336 · Beijing Biotech Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 14 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing consent - People who have been diagnosed with glioblastoma (a type of aggressive brain tumour, WHO grade 4) or a related high-grade brain tumour (WHO grade 3 or 4) that has come back or continued to grow after standard tr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07552233 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old (inclusive), of any gender - People who have at least one tumour that can be assessed, with a confirmed diagnosis of a malignant brain or central nervous system tumour, and imaging showing the tumour has continued to grow or come back after tre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07560865 · Masonic Cancer Center, University of Minnesota Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a Grade 4 astrocytoma (a type of aggressive brain tumor), confirmed by a tissue sample, and your tumor's genetic markers (IDH mutation and MGMT methylation) have been tested — though the results won't affect eligibility. - Your brain tumor has co...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07563777 · Longevity Metrics, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2099
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who are willing and able to sign a consent form, or who have a legally authorised representative (such as a family member or carer) who can provide consent on their behalf - People who are willing to take part in follow-up appointments or ch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07567196 · Universita degli Studi di Genova Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇮🇹 IT

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a serious type of brain tumor (called a high-grade glioma, WHO grade III or IV) that was identified on an MRI scan - You are able and willing to sign a consent form agreeing to take part in the trial Who may not be abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07594262 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇮🇹 IT

Who might be able to join this trial: - A doctor has recommended surgery to remove a pituitary gland tumour (called a PitNET) based on current medical guidelines - The person has not taken any medication to treat the pituitary tumour before having it surgically removed - The pituitary tumour has been confirmed through...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07608003 · Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with diffuse gliomas (a type of brain tumour) confirmed through both tissue testing and molecular testing. - People whose complete medical records and case information are available. - People who had an MRI scan done before their surgery. Who may n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07612917 · Johannes Kepler University of Linz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇦🇹 AT

**Who might be able to join this trial:** - People diagnosed with a type of brain tumour called a diffuse glioma, graded between 2 and 4 on the WHO scale - People aged between 18 and 65 years old - People who have read the participant information and signed a consent form agreeing to take part in the study - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07620470 · Philips Clinical & Medical Affairs Global Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a brain tumor based on clinical assessment and brain imaging (such as an MRI or CT scan) - People who have had a contrast-enhanced scan performed using a specific CT scanner called the Spectral CT 7500 - People who are 18 years of age or older...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07623577 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People whose general health and ability to carry out daily activities falls within a certain range, as assessed by a standard medical scale (called ECOG Performance Status 0–2, meaning fully active to capable of limited self-care — confirm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07627334 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇦🇹 AT

**Who might be able to join this trial:** - You are generally able to carry out your daily activities, even if you have some limitations (your doctor rates your physical ability as 0, 1, or 2 on a standard scale) - You have been recently diagnosed with a specific type of brain tumour called glioblastoma (IDH-wildtype)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07631338 · Hospital Italiano de Buenos Aires Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇦🇷 AR

**Who might be able to join this trial:** **Group 1:** - You must be 18 years old or older and be a member of the health insurance plan at Hospital Italiano de Buenos Aires. - You must have had at least 1 year of documented medical follow-up during the study period. **Group 2:** - You must be 18 years old or older an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07632092 · Centre Hospitalier Universitaire, Amiens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 November 2028
🇫🇷 FR

**Who might be able to join this trial:** - You have been referred for a specific type of brain scan (called an FDG-PET scan) as part of your regular medical care to check for cancer that has spread to the brain (brain metastases) - You are 18 years of age or older - You are covered by a social security/health insuranc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07638852 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old, any gender - People whose general health and ability to carry out daily activities falls within an accepted range on a standard medical scale (ECOG score 0–2) (confirm with trial site) - People who have been diagnosed through lab testing with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07642856 · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 July 2032
🇺🇸 US

Who might be able to join this trial: - People aged between 18 and 75 years old - Both men and women are eligible - People who have a condition that mainly affects the cerebellum (a part of the brain that controls balance and coordination), such as damage caused by a stroke, a brain tumour, or a degenerative condition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07646782 · Longevity Metrics, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2099
🇺🇸 US

Who might be able to join this trial: - People who are enrolled in the 100-Year Human Aging Study at a fixed or mobile clinical site, or who have completed an online health screening questionnaire and provided location information along with their consent. Who may not be able to join: - People who are under 18 years o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07648823 · Beijing Tiantan Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 20 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have fully understood the study and have voluntarily signed a consent form agreeing to take part. - People aged 18 to 80 years old. - People whose general physical functioning is rated at a good to fully active level on a standard oncology scale (ECOG score of 0 o...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07655869 · Beijing Tiantan Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed a consent form agreeing to take part in the study. - Adults aged 18 or older. - People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by laboratory analysis of tissue taken during surgery or biopsy. - People taking steroi...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07657403 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with a brain tumor located near areas of the brain involved in language, movement, or major brain communication networks. - People whose general health and ability to carry out daily activities meets a certain minimum level, as measured b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07660458 · West China Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** **For children:** - The child has been diagnosed with medulloblastoma (a type of brain tumor) that has come back, confirmed by a scan or tissue sample - The child is 18 years old or younger at the time of joining the trial - The child is currently receiving active treatment fo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07668869 · Prof. Franciszek Lukaszczyk Memorial Oncology Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇵🇱 PL

Who might be able to join this trial: - Adults aged 18 or older - People whose ability to carry out daily activities meets a minimum level, as measured by a standard medical scale called the Karnofsky Performance Status (score of 70 or above) - People who have been diagnosed with a specific type of brain tumour called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07675070 · NanoAlvand Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
Iran

Who might be able to join this trial: - People who have been newly diagnosed with a grade III or IV brain tumour (a type called a glial tumour), or whose brain tumour has come back or gotten worse after standard treatment, and whose doctor has decided they need a medicine called temozolomide - People between the ages o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07703761 · Università degli Studi di Trento Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇮🇹 IT

Who might be able to join this trial: - People who had an MRI scan confirming a glioma (a type of brain tumour) diagnosis between 2019 and 2024, with medical records available covering the cancer type, stage, and treatment history - People who had a full surgical removal of their brain tumour, whether or not this was f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Brain Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Cure Brain Cancer Foundation is the national body funding brain cancer research and supporting affected families.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.